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As drug development is time consuming and costly, compounds that are 
likely to fail should be weeded out early through the use of assays and toxicity 
screens. Computational methods are favourable complementary techniques. 
Nevertheless, it is not exploited to its full potential due to: models that were built 
from small data sets, a lack of applicability domain (AD), not being readily 
available for use, not following the Organisation for Economic Co-operation and 
Development(OECD) quantitative structure-activity relationship(QSAR) 
validation guidelines in developing a QSAR model, and due to static nature of the 
protein structure obtained from X-ray crystallography, difficulties in consistency 
and reproducibility of each docking process and result, and the absence of a 
strong correlation between the predicted binding modes and the actual biological 
activity of the compound in in vitro experiments in docking studies. 
 
 This thesis attempts to address these problems with the following 
strategies. First, the data augmentation approach using putative negatives was 
used to increase the information content of data sets. Second, ensemble methods 
were investigated as the approach to improve accuracies of QSAR models. Third, 
predictive models are to be built from data sets as large as possible, with the 
application of AD to define the usability of these models. Fourth, the QSAR 
models were built according to the guidance set out by the OECD. Fifth, the 
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models were packaged into a free software to facilitate independent evaluation 
and comparison of QSAR models. 
 
 The usefulness of these strategies were evaluated using structure activity 
relationship(SAR) data set in c-Jun N-terminal kinase (JNK) inhibitors. The 
compounds were used in QSAR modeling, docking, pharmacophore mapping and 
molecular dynamics simulations to refine the list of inhibitors. To the best of our 
knowledge, the models are from significantly larger training data with the effects 
of increased AD and reduced false positive hits.  
 
 In structure-based approaches, the compounds obtained from the 
consensus models obtained were docked by using a variety of rigid and flexible 
docking methods, pharmacophore mapping and molecular dynamics simulations 
as well as various modeling algorithms and different docking software to prepare 
the structure of the enzyme and to obtain a consensus of different docking results 
to improve on the correlation between the prediction made by the docking 
software and the actual biological activity of the compound in the in vitro setting. 
The various approaches are useful, to varying extents, for improving the virtual 
screening of potential drug leads for specific pharmacodynamic properties.  
 
 The results of the virtual screening project on JNK inhibitors prioritized 1 
compound targeting the JNK-Interacting Protein 1(JIP1) binding site of JNK1. A 
set of compounds that target the DFG binding site of JNK2 were also tested for 
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inhibitory activity after a docking study. One compound showed 20% inhibition 
on JNK1, and one compound showed 19% inhibition on JNK2 at a concentration 
of 40 µM. 
 
 To further refine and improve on structure-based methods used in this 
project, an in silico study was carried out on a set of approved drugs and one 
chemical compound available at PubChem. The aims of this study are to form a 
prediction model for both human and zebrafish pregnane X receptor (PXR) 
activators and non-activators due to the lower cost and shorter waiting period to 
obtain CYP3A4 gene expression data in zebrafish as decided and advised by 
collaborators. A docking study with simple energy minimization and homology 
modeling techniques was initially carried out. Docked poses would be identified 
using hierarchical clustering. The binding orientation of each compound would be 
identified using this method. 
 
This study would eventually include pharmacophore mapping and 
molecular dynamics simulations to refine the model and provide an additional 
filter mechanism. Through molecular dynamics simulations, the stability of the 
trajectory, protein movement that is predicted to occur in the complex between 
PXR and retinoid X receptor (RXR), the duration of the ligand inside the ligand 
binding domain (LBD) of PXR and the length and duration of hydrogen bonds 
and pi interactions that are formed between the ligand and the receptor are 
obtained in this study. A more accurate prediction model was developed in this 
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phase of the project where zebrafish PXR activators are predicted to form 
interactions with at least one conserved residue that is also present in human PXR, 



















List of Tables 
2.1 Performance of consensus model on each validation set and on the entire 
dataset ……………………………………………………………………36 
2.2 Virtual screening of ZINC library using consensus model ……………38 
2.3 Structural diversity of compounds ……………………………………39 
2.4 A selection of ZINC compounds not reported as JNK inhibitors that are 
the most dissimilar from the positive compound BI-78D3 ……………40 
2.5 Descriptors used in the consensus model ……………………………42 
3.1 List of pharmacophore points selected in model ……………………46 
3.2 Docking results using Molecular Operating Environment ……………51 
3.3 Chemical structures of validation compounds ……………………56 
3.4 Chemical structures and docking scores for molecular dynamics 
trajectories of 3 ns duration ……………………………………………58 
3.5 Cluster size and total population of each compound ……………………59 
3.6 Distance between geometric center of aromatic ring in compound and Arg 
127 ……………………………………………………………………70 
3.7 Distance between large atoms in Arg 127 of JNK1 and compound ……75 
4.1 Results of docking scores on various ZINC compounds using different 
docking software ……………………………………………………81 
4.2 KINOMEScan assay results ……………………………………………84 
5.1 List of docked scores ……………………………………………………92 
5.2 Amino acid residues involved in the binding of compounds to human PXR 
…………..………………………………………………………………..94 
 
5.3 Distance between first set of compounds and residue where potential 
hydrogen bond interactions might be present …………………………..102 
6.1 List of amino acid residues that form the ligand-binding domain in human 
PXR and zebrafish PXR …………………………………………..110 
6.2 List of docked scores …………………………………………………..112 
xiv 
 
6.3 Amino acid residues involved in the binding of compounds to human PXR 
 …………………………………………………………………………..113 
6.4 Amino acid residues involved in the binding of compounds to zebrafish 
PXR …………………………………………………………………..114 
 
6.5 Distance between second set of compounds and residue where potential 
hydrogen bond interactions might be present …………………………..145 
 
6.6 Distance between geometric center of aromatic rings in second set of 

















List of Figures 
1.1 Ribbon diagram of JNK with stick and surface representation of ligand in 
each binding pocket ……………………………………………………10 
 
2.1 Flowchart of steps taken to obtain the training and validation set ……31 
3.1 Ribbon structure of JNK1 with truncated JIP1 ................................45 
3.2 Close-up of truncated JIP1 in binding pocket of JNK1 ……………45 
3.3 Pharmacophore model developed using MOE 2012.10 ……………47 
3.4 Flowchart of steps taken in this virtual screening workflow ……………55 
3.5 Pose of Compound 19 ............…………………………………………....62 
 
3.6 Graph of distance between geometric center of aromatic ring in 
Compound 19 and Arg 127 against instance in trajectory ……………62 
3.7 Graph of distance between geometric center of aromatic ring in 
Compound 25 and Arg 127 against instance in trajectory ……………63 
3.8 Pose of Compound 19 over ribbon diagram of JNK1 ……………63 
 
3.9 Pose of Compound 19 over ribbon diagram of JNK1with polar residues 
 ……………………………………………………………………………64 
3.10 Pose of Compound 19 over ribbon diagram of JNK1 with hydrophobic 
residues ……………………………………………………………64 
3.11 Pose of Compound BI-98A10 ........................................................65 
3.12 Pose of Compound BI-90H8 ……………………………………………65 
3.13 Graph of distance between geometric center of aromatic ring in 
Compound BI-98A10 and Arg 127 against instance in trajectory ……66 
3.14 Graph of distance between geometric center of aromatic ring in 
Compound BI-90H8 and Arg 127 against instance in trajectory ……66 
3.15 Pose of Compound BI-98A10 over ribbon diagram of JNK1 with polar 
residues ……………………………………………………………67 




3.17 Pose of Compound BI-98A10 over ribbon diagram of JNK1 with 
hydrophobic residues ……………………………………………………68 
3.18 Pose of Compound BI-90H8 over ribbon diagram of JNK1 with 
hydrophobic residues ……………………………………………………68 
3.19 Graph of distance between geometric center of aromatic ring in 
Compound BI-83B3 and Arg 127 against instance in trajectory ……69 
3.20 Graph of distance between geometric center of aromatic ring in 
Compound 3 and Arg 127 against instance in trajectory ……………69 
3.21 Graph of distance between geometric center of aromatic ring in 
Compound 10 and Arg 127 against instance in trajectory ……………70 
3.22 Pose of Compound BI-90H8 ……………………………………………71 
3.23 Graph of distance between large atom in Compound BI-90H8 and Arg 127 
against instance in trajectory ……………………………………………71 
3.24 Graph of distance between large atom in Compound BI-90E2 and Arg 127 
against instance in trajectory ……………………………………………72 
 
3.25 Graph of distance between large atom in Compound BI-90E7 and Arg 127 
against instance in trajectory ……………………………………………72 
3.26 Pose of ZINC03405497 …………………………………………....73
  
3.27 Graph of distance between large atom in ZINC03405497 and Arg 127 
against instance in trajectory ……………………………………………74 
 
3.28 Pose of ZINC03405497 over ribbon diagram of JNK1 with charged 
residues ……………………………………………………………74 
3.29 Pose of ZINC03405497 over ribbon diagram of JNK1 with hydrophobic 
residues ……………………………………………………………75 
5.1 Correlation curve for MM/GBVI binding free energy against fold increase 
in human PXR activity over vehicle control ……………………………93 
5.2 Correlation curve for molecular weight against fold increase in human 
PXR activity over vehicle control ……………………………………93 
5.3 Pose of etravirine ……………………………………………………95 
5.4 Graph of distance between large atom in etravirine and Gln 285 against 




5.5 Pose of etravirine over ribbon diagram of human PXR with hydrophobic 
residues ……………………………………………………………96 
 
5.6 Pose of rilpivirine ……………………………………………………97 
5.7 Graph of distance between large atom in rilpivirine and Gln 285 against 
instance in trajectory ……………………………………………………97 
 
5.8 Pose of rilpivirine over ribbon diagram of human PXR with hydrophobic 
residues ……………………………………………………………98 
 
5.9 Pose of efavirenz ……………………………………………………98 
 
5.10 Graph of distance between large atom in efavirenz and His 407 against 
instance in trajectory ……………………………………………………99 
5.11 Pose of efavirenz over ribbon diagram of human PXR with hydrophobic 
residues ……………………………………………………………99 
 
5.12 Graph of distance between large atom in efavirenz and His 407 against 
instance in trajectory …………………………………………………..100 
5.13 Graph of distance between large atom in PCN and His 407 against 
instance in trajectory …………………………………………………..101 
 
5.14 Graph of distance between large atom in nevirapine and His 407 against 
instance in trajectory …………………………………………………..101 
 
6.1 Amino acid sequence for homology model of zebrafish PXR and human 
PXR using PDB structure 1SKX as template …………………………..106 
 
6.2 Ramachandran plot of X-ray structure of human PXR …………..107 
 
6.3 Ramachandran plot of homology model of zebrafish PXR …………..108 
 
6.4 Graph of distance between large atom in rifampicin and Ser 247 against 
instance in trajectory …………………………………………………..116 
 
6.5 Graph of distance between large atom in rifampicin and Thr 247 against 
instance in trajectory …………………………………………………..116 
 
6.6 Pose of phenytoin in human PXR …………………………………..117 
6.7 Graph of distance between large atom in phenytoin and Gln 285 against 




6.8 Pose of phenytoin over ribbon diagram of human PXR with hydrophobic 
residues …………………………………………………………..118 
6.9 Pose of phenytoin in zebrafish PXR …………………………………..118 
6.10 Graph of distance between geometric center of aromatic ring in phenytoin 
and Phe 288 against instance in trajectory …………………………..119 
6.11 Pose of phenytoin over ribbon diagram of zebrafish PXR with 
hydrophobic residues …………………………………………………..119 
6.12 Pose of carbamazepine in human PXR …………………………..120 
6.13 Graph of distance between large atom in carbamazepine and Ser 247 
against instance in trajectory …………………………………………..121 
6.14 Pose of carbamazepine over ribbon diagram of human PXR with 
hydrophobic residues …………………………………………………..121 
6.15 Pose of carbamazepine in zebrafish PXR …………………………..122 
6.16 Graph of distance between large atom in carbamazepine and Phe 288 
against instance in trajectory …………………………………………..122 
6.17 Pose of carbamazepine over ribbon diagram of zebrafish PXR with 
hydrophobic residues …………………………………………………..123 
6.18 Pose of dexamethasone in human PXR …………………………..124 
6.19 Graph of distance between large atom in dexamethasone and Gln 285 
against instance in trajectory  …………………………………..124 
6.20 Pose of dexamethasone over ribbon diagram of human PXR with 
hydrophobic residues …………………………………………………..125 
6.21 Pose of dexamethasone in zebrafish PXR  …………………..125 
6.22 Graph of distance between large atom in dexamethasone and Met 323 
against instance in trajectory …………………………………………..126 
6.23 Pose of dexamethasone over ribbon diagram of zebrafish PXR with 
hydrophobic residues …………………………………………………..126 
6.24 Pose of nafcillin in human PXR …………………………………..127 
6.25 Graph of distance between large atom in nafcillin and Gln 285 against 
instance in trajectory …………………………………………………..128 
xix 
 
6.26 Pose of nafcillin over ribbon diagram of human PXR with hydrophobic 
residues …………………………………………………………..128 
6.27 Pose of nafcillin in zebrafish PXR …………………………………..129 
6.28 Graph of distance between large atom in nafcillin and Met 323 against 
instance in trajectory …………………………………………………..129 
6.29 Pose of nafcillin over ribbon diagram of zebrafish PXR with hydrophobic 
residues …………………………………………………………..130 
6.30 Pose of efavirenz in zebrafish PXR …………………………………..131 
6.31 Graph of distance between large atom in efavirenz and Met 323 against 
instance in trajectory  …………………………………………..131 
6.32 Pose of efavirenz over ribbon diagram of zebrafish PXR …………..132 
6.33 Pose of pioglitazone in zebrafish PXR …………………………..133 
6.34 Graph of distance between geometric center of aromatic ring in 
pioglitazone and Trp 299 in zebrafish PXR against instance in trajectory 
 …………………………………………………………………………..133 
 
6.35 Pose of pioglitazone over ribbon diagram of zebrafish PXR with 
hydrophobic residues …………………………………………………..134 
 
6.36 Graph of distance between geometric center of aromatic ring in 
pioglitazone and Trp 299 in human PXR against instance in trajectory 
 …………………………………………………………………………..134 
 
6.37 Pose of prednisone in human PXR …………………………………..135 
 
6.38 Graph of distance between large atom in prednisone and Gln 285 against 
instance in trajectory …………………………………………………..136 
 
6.39 Pose of prednisone over ribbon diagram of human PXR with hydrophobic 
residues …………………………………………………………..136 
 
6.40 Pose of prednisone in zebrafish PXR …………………………………..137 
 
6.41 Graph of distance between large atom in prednisone and Met 323 against 
instance in trajectory …………………………………………………..137 
 
6.42 Pose of prednisone over ribbon diagram of zebrafish PXR with 




6.43 Graph of distance between large atom in rufinamide and Ser 247 against 
instance in trajectory …………………………………………………..139 
 
6.44 Graph of distance between large atom in rufinamide and Gln 285 against 
instance in trajectory …………………………………………………..139 
 
6.45 Graph of distance between large atom in rufinamide and His 407 against 
instance in trajectory …………………………………………………..140 
 
6.46 Graph of distance between geometric center of aromatic ring in rufinamide 
and Phe 288 in human PXR against instance in trajectory …………..140 
 
6.47 Graph of distance between large atom in rufinamide and Met 323 against 
instance in trajectory …………………………………………………..141 
 
6.48 Graph of distance between geometric center of aromatic ring in rufinamide 
and Phe 288 in zebrafish PXR against instance in trajectory …………..141 
 
6.49 Graph of distance between geometric center of aromatic ring in rufinamide 
and Trp 299 in zebrafish PXR against instance in trajectory …………..142 
 
6.50 Graph of distance between large atom in acetaminophen and Ser 247 
against instance in trajectory …………………………………………..142 
 
6.51 Graph of distance between large atom in acetaminophen and Gln 285 
against instance in trajectory …………………………………………..143 
 
6.52 Graph of distance between large atom in acetaminophen and His 407 
against instance in trajectory …………………………………………..143 
 
6.53 Graph of distance between geometric center of aromatic ring in 
acetaminophen and Phe 288 in human PXR against instance in trajectory 
 …………………………………………………………………………..144 
 
6.54 Graph of distance between large atom in acetaminophen and Met 323 
against instance in trajectory ………………………………………......144 
 
6.55 Graph of distance between geometric center of aromatic ring in 












 Eukaryotic cells undergo a wide range of metabolic processes in order to 
function effectively. For many of these metabolic processes that occur in 
mammalian and human cells, enzymes are involved to catalyze a wide range of 
chemical reactions that are necessary to bring about changes to the cell. Important 
enzyme families that are currently being studied includes the protein kinase and 
the cytochrome monooxygenase family. 
  
The protein kinase family consists of 518 kinases[1] and due to their 
critical role in phosphorylation of proteins, they played important roles in many 
aspects of cellular physiology which include cell division, proliferation, 
differentiation and apoptosis. Therefore, the design of drugs which inhibit protein 
kinases have been carried out by the pharmaceutical industry for over 20 years. 
There are currently 14 Food and Drug Administation (FDA) approved small 
molecule drugs which target protein kinases on the market, in addition to many 
more kinase inhibitors currently in clinical trials. Furthermore, it is estimated that 





 One class of protein kinase is mitogen-activated protein kinase (MAPK) 
enzymes that are activated in response to external environmental stimuli such as 
stress. Previously named as stress-activated protein kinase (SAPK), MAPK 
enzymes consist of c-Jun N-terminal kinase (JNK) enzymes, p38 enzymes and 
extracellular signal regulating kinase (ERK) enzymes where they catalyze the 
reaction of adenosine triphosphate (ATP) and a protein to adenosine diphosphate 
(ADP) and a phosphoprotein[4-9]. Among these, JNK is particularly interesting as 
it has been linked to several human diseases such as stroke, diabetes, 
atherosclerosis, neurodegenerative diseases, autoimmune and inflammatory 
diseases, multiple sclerosis, asthma, inflammatory bowel disease, psoriasis and 
cancer[10-12]. 
 
 The cytochrome P450 monooxygenase family consists of 57 enzymes and 
may be found in all tissues[13]. Cytochrome P450 enzymes have an important 
role in metabolism, activation and detoxification of various chemical compounds, 
drugs and xenobiotics that are taken in by the human body. Therefore, 
cytochrome P450 induction and inhibition data are required to obtain regulatory 
approval for various drugs and chemical compounds. Human liver cells may be 
used as a biomarker to investigate cytochrome P450 activity[14]. Cytochrome 





 Expression of the gene that encodes for the cytochrome P450 family 3 
subfamily A polypeptide 4 (CYP3A4) monooxygenase enzyme is strongly 
correlated with activation of Pregnane X Receptor (PXR) and the heterodimer 
being formed between PXR and Retinoid X Receptor (RXR)[17-21]. PXR and 
RXR are nuclear receptors which are part of a superfamily of 48 transcription 
factors[22]. PXR activity has important roles in regulating drug metabolism and 
drug transportation, along with other completely different processes such as 
karyopherin-mediated nuclear import. PXR also has the capacity to accept and 
bind to a very large variety of different drugs and chemical compounds of various 
molecular weights[23]. Therefore, the study of PXR activity is interesting as 
expression of CYP3A4 gene could potentially be used as a screening mechanism 
to predict and reduce drug and xenobiotic metabolism and toxicity.  
 
1.1 Physiology of JNK 
  
 JNKs are serine/threonine protein kinases which fall within the CMGC 
group of protein kinases and consist of three isoforms, JNK1, JNK2 and 
JNK3[24]. JNK1 and JNK2 are found in all parts of the human body[25,26], and 
JNK3 are found predominantly in the brain, heart and testes[27-29]. JNK 
enzymes catalyze the transfer of a phosphate group from adenosine triphosphate 
(ATP) that is present throughout the human body to a protein to form a 
phosphoprotein and adenosine diphosphate (ADP). This protein consists of a c-
Jun component that is present in activator protein-1 (AP-1) which gives JNK its 
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name. c-Jun is the name for the messenger RNA codon which codes for the 
residue and structure of the protein that contains the c-Jun component. The c-Jun 
component of AP-1 has two serine residues which will bind to Thr183, Pro184 
and Tyr185 of JNK (PDB ID: 3ELJ). ATP will bind at the ATP binding site of 
JNK, where a phosphate group from ATP will be transferred over to the c-Jun 
component of AP-1 and similar proteins with a c-Jun component. ATP will 
become ADP, and the protein will become a phosphoprotein. The phosphoprotein 
will then proceed further along the metabolic pathway, where if the 
phosphoprotein is produced constantly in response to stress, it will lead to a wide 
range of metabolic disorders, inflammatory and immune reactions, and 
neurodegenerative disorders. 
  
1.2 Inhibition of JNK 
 
Since JNK was discovered in the 1990s, there have been studies to test the 
effects of inhibiting the enzyme as well as removal of one or more JNK isoform 
through gene knockout on animal studies and on cell studies. The results show 
increased insulin sensitivity on insulin receptors[30], improved arthritic 
scores[31], and improved neural function[32] in mice exposed to high lipid diet, 
inflammatory disease and neurotoxins. In cancer cell lines, there is also a 
reduction in cancer cell growth and size when JNK is inhibited in the in vitro 
setting[33,34]. Inhibition of JNK will cause ATP to bind less easily to the ATP 
binding site. The entire protein will eventually be broken down and removed by 
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an ubiquitin pathway. Hence, by inhibiting this part of the metabolic pathway, it 
could provide benefits in treating and preventing the various human diseases that 
are caused due to activation of the JNK pathway[29]. These diseases include 
stroke[35], type-2 diabetes, atherosclerosis, neurodegenerative diseases including 
Alzheimer's, Parkinson's and Huntington's diseases, autoimmune and 
inflammatory diseases including rheumatoid arthritis, multiple sclerosis, asthma, 
inflammatory bowel disease, psoriasis and cancer[10-12]. 
 
JNK can be inhibited by both competitive and non-competitive methods to 
reduce the activity of the enzyme. A competitive inhibitor occupies the ATP 
binding site to block ATP from binding. A non-competitive inhibitor will bind at 
an allosteric site on the JNK enzyme which causes the tertiary structure of JNK to 
fold and reduce the space of the ATP binding pocket. This increases the amount 
of steric hindrance at the ATP binding pocket, making ATP less likely to bind to 
the ATP pocket. There are currently two known non-competitive sites, one of 
them is the JNK interacting protein (JIP) site where there is a protein that is very 
specific to bind only to JNK at this site, and the other is the DFG site which is 
named after the one letter symbol of the aspartic acid, phenylalanine and glycine 
residues that are present at that binding site in JNK. For all three JNK isoforms, 
the ATP pocket, JIP pocket and DFG pocket have high sequence identity. 
 
X-ray crystal structures of JNK have shown that their binding site residues 
have a high degree of similarity between all three JNK isoforms. This leads to the 
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obstacle in designing relatively selective small molecule inhibitors where the 
electrostatics and shape of the binding site tend to be similar. As a result of the 
highly-conserved structures of functional motifs present in JNKs and kinases in 
general, this makes developing relatively selective inhibitors for JNKs 
difficult[36]. 
 
For competitive inhibition, designing inhibitors that target the ATP site are 
likely to have more potential selectivity and specificity problems since there are 
many kinase enzymes that use ATP as a substrate. This could lead to an increase 
in side effects if the other kinase enzymes that are affected do not contribute to 
the disease process. Designing inhibitors that target the JIP or DFG site are 
expected to be more novel and have a less saturated chemical space to explore,  
hence this research project will attempt to address this knowledge gap. Some 
existing inhibitors, such as the set of compounds published by Chen et al, and the 
drug, imatinib were found to bind to both the ATP binding site, as well as the JIP 
or DFG binding site[37]. 
 
1.2.1 ATP binding site 
 
 The ATP binding site is the most widely studied among the three binding 
site as it was identified when JNK was discovered. The first small-molecule 
inhibitor targeting the ATP binding site was discovered in 2001[38], and more 
than 900 compounds that target this site have since been published and registered 
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on patent databases as a novel inhibitor of JNK. The majority of published studies 
which examine the effects of inhibition of JNK using in silico, in vitro and in vivo 
models also use ATP competitive inhibitors[37,39-54]. The ATP binding site 
consists of 9 hydrophobic residues (Val 40, Ala 53, Ile 86, Met 108, Leu 110, Met 
111, Ala 113, Val 158 and Leu 168) and 2 polar and charged residues (Glu 109 
and Asp 112) from X-ray crystal structure of SP600125 complex with JIP1 and 
JNK1 (PDB entry: 1UKI)[55-58]. Inhibitors which bind at this active site are 
referred to as Type I inhibitors and usually meet the pharmacophore model by 
Traxler[59] as well as by forming hydrogen bonds with Glu 109 and/or Met 111 
at the hinge region. 
 
1.2.2 JIP binding site 
 
The JNK-interacting protein (JIP) binding site has been discovered and 
published in detail where a study by Barr et al have discovered a small and 
truncated form of JIP consisting of only 11 amino acid residues of JIP to be 
sufficient to start the inhibition mechanism of JNK at the JIP active site[60]. JIP1 
is a scaffold protein which binds to JNK1 and reduces the volume of the ATP-
binding site. This produces an inhibitory effect where one unit of ATP cannot 
bind to one unit of JNK1 and activate JNK1. JIP1 was found to bind to JNK1 and 
JNK2, and did not bind to ERK and p38 enzymes. Hence, JIP1 inhibitors that 
target the JIP1 binding site of JNK1 are postulated to have greater selectivity and 
specificity and fewer side-effects[61]. Currently, there are at least 191 compounds 
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targeting the JIP1 binding site of JNK1 with published biological activity data 
since the first small molecule inhibitor targeting this site was published in 
2008[62] and one X-ray crystal structure of the truncated JIP1 structure in 
complex with JNK1[57]. 
 
 The JIP binding site consists of 9 hydrophobic residues (Ala 113, Leu 115, 
Val 118, Met 121, Leu 123, Leu 131, Val 159, Val 323 and Trp 324), 3 polar 
residues (Tyr 130, Ser 161 and Cys 163) and 3 polar and charged residues (Glu 
126, Arg 127 and Glu 329). Inhibitors which bind at this site are Type III 
inhibitors and may bind at any subsite that JIP binds to on JNK which is away 
from the ATP binding site. The binding site is shallow and is exposed to solvent 
to one side. Due to the polar and charged residue Arg 127 having a potential 
effect on conferring selectivity to ligands[63] and the novelty of exploring 
compounds which can bind to this subsite, this research project will attempt to 
screen and identify potential compounds from the ZINC database that can bind to 
the selected subsite using ligand and structure-based methods.  
 
1.2.3 DFG binding site 
 
 The DFG binding site has been identified from studies of the p38 enzyme 
that has the same enzyme classification number of JNK and fulfills a different 
role in metabolic reactions. The DFG binding site consists of a hydrophobic 
pocket adjacent to the ATP binding site. This binding site has an aspartic acid, 
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phenylalanine and glycine amino acid residue which make up the DFG motif 
where the phenylalanine residue can adopt a DFG-in conformation and a DFG-out 
conformation. Different kinase enzymes have different capacity to accept and 
bind to DFG site inhibitors at the DFG-in or DFG-out conformation. For binding 
of small-molecule inhibitors to occur favourably, the DFG binding site in p38 and 
JNK has to be in the DFG-out conformation, where the phenylalanine residue 
partially occupies the ATP site, has one face that helps to shield the DFG-out 
inhibitor, while the other face is exposed to solvent. However, DFG adopts this 
conformation only rarely[64]. Furthermore, the X-ray crystal structure of the 
compound BIRB798 with the JNK enzyme was only produced in 2010 (PDB 
Entry 3NPC). Hence, these factors led to the relatively lack of known DFG 
inhibitors. Inhibitors that bind at this site will block the ATP binding site by 
inducing the DFG-out conformation. This form of partial inhibition of JNK is 
more desirable than the Type I inhibition mechanism by having greater selectivity 
and specificity and fewer side-effects. There is currently a large knowledge gap in 
this area as only one compound has been found to bind to this binding site in 
JNK2 and one X-ray crystal structure of the compound at the DFG binding site of 
JNK2[65].  
 
 The DFG binding site consists of 12 hydrophobic residues (Ile 32, Val 40, 
Ala 53, Leu 76, Leu 77, Ile 86, Met 108, Leu 110, Met 111, Leu 142, Leu 168 and 
Phe 170), 1 polar residue (Gln 37) and 6 polar and charged residues (Lys 55, Arg 
69, Arg 72, Glu 73, Glu 109 and Asp 169). Inhibitors which bind at this site are 
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Type II inhibitors and occupies a deep hydrophobic pocket away from the ATP 
binding site to produce the DFG out conformation, as well as a section of the ATP 
binding site at the hinge region. Hence, this type of inhibition can be considered 
to be competitive by strict definition, and deep pocket binders due to the deep-
pocket interactions where DFG adopts which is away from the hinge region which 
ATP occupies[66]. Figure 1.1 shows each binding site in JNK. 
 
Figure 1.1: Ribbon diagram of JNK with stick and surface representation of 
ligand in each binding pocket. Amino terminal domains are 
coloured in blue and carboxyl terminal domains are coloured in 
red. Bis-anilino-pyrrolopyrimidine inhibitor in ATP binding pocket 
shown as grey stick and surface (PDB ID: 3ELJ). Truncated JIP in 
JIP binding pocket shown as green stick and surface (PDB ID: 
1UKH). BIRB796 in DFG binding pocket shown as pink stick and 







1.3 Physiology of PXR 
 
Human PXR was discovered in 1998 and was termed an orphan nuclear 
receptor[20] and nuclear receptor subfamily 1 group I member 2 (NR1I2)[67]. 
Found mainly in liver and intestinal cells, PXR have important roles in 
maintaining homeostasis and metabolism of bile acids, glucose, lipids, drugs, 
endocrine hormones and xenobiotics with another nuclear receptor Constitutive 
Androstane Receptor(CAR)[68]. Expression of PXR and CAR are activated by 
Glucocorticoid Receptor (GR)[69]. 
 
PXR forms a heterodimer complex with RXR through 21 amino acid 
residues[70]. Activation of PXR and formation of this complex with RXR 
regulates expression of genes that are involved in drug and xenobiotic sensing, 
metabolism and transport which include cytochrome P-450 family 3 subfamily A 
polypeptide 4 (CYP3A4) genes, where approximately 50% of marketed 
prescription drugs are metabolized by CYP3A4[71-73]. Hence, expression of 
CYP3A4 genes are regulated by GR, PXR, RXR and CAR directly or 
indirectly[74].  
 
 PXR activity consists of basal activity which is ligand-independent and 
ligand-dependent activity[75]. Ligand-dependent activity is influenced by the 
presence of ligands which bind to the ligand-binding domain (LBD) of PXR 
where different ligands may exert an agonist[74], antagonist[76] or partial 
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agonist[77] effect on the nuclear receptor. PXR is present in many species and 
may exhibit differences in selectivity of small molecule compounds in its ligand-
binding domain[78]. 
 
1.4 Current drug discovery efforts to identify JNK inhibitors and PXR 
activators 
 
Known JNK inhibitors have limited structural diversity. This is partly due 
to the fact that most are ATP-competitive inhibitors and the ATP binding pocket 
is highly conserved. Another reason for the low structural diversity is that most 
existing JNK inhibitors were discovered through high-throughput screening 
(HTS) followed by lead optimization using traditional medicinal chemistry 
approach. This is a time-consuming process and usually only evaluate a limited 
amount of structural diversity in each study. High-throughput screening (HTS) 
can improve the speed of searching for novel JNK inhibitors but is not practical 
for screening large chemical libraries with millions of compounds which would 
be more expensive. Furthermore, recent studies show that fewer drugs have 
entered the market with fewer compounds passing clinical trials, greater difficulty 
in obtaining approval from regulators and a high dropout rate[79,80]. 
 
Among the JNK inhibitors that were found to target the JIP binding site, 
they were discovered through HTS. In a HTS assay that was carried out to 
discover the first JIP-site inhibitor, it screened a total of 30000 compounds at a 
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rate of 20 compounds per assay.  From the first lead compound BI-78D3 that was 
discovered as a hit, it was tested in murine models to assess safety and 
efficacy[62]. The subsequent lead and structural modifications would create a list 
of one to three classes of compounds[81-84]. 
 
Issues of compound selectivity and safety remain mainly for competitive 
inhibitors targeting the ATP binding site. This is because it is difficult to design 
small-molecule inhibitors that would only inhibit one isoform of JNK due to the 
highly conserved ATP binding site among all three JNK isoforms and in other 
protein kinases. Hence, the use of these JNK inhibitors beyond in vitro assays 
remain limited[10,11]. Inhibitors that target the JIP binding site and DFG binding 
site are less likely to bind to other kinase enzymes in a panel of related and 
unrelated kinase screening tests. 
 
For PXR activity, there are studies being carried out to determine the type 
of ligand-dependent activity on the nuclear receptor as it could potentially be used 
as a model to assess and predict drug-drug interactions as well as effects of 
xenobiotics such as environmental pollutants and toxins occurring within human 
cells and the human body[17,76,85]. There are also studies being carried out to 
determine the differences in PXR shape and structure among different species, 
and how these differences affect interactions of PXR with various drug and 




1.5 Computational methods to screen and validate JNK inhibitors and 
PXR activators 
 
 To screen large chemical libraries that contain millions of compounds to 
test for inhibitory activity on JNK in cell and animal models would be expensive 
and time-consuming. It is also expensive and time-consuming to conduct in vitro 
and in vivo tests for CYP3A4 and PXR activity. Computational methods are a fast 
and cost-effective method for complementing traditional drug development 
methods. With the introduction of computers with higher processing capacity, 
together with X-ray crystallography or nuclear magnetic resonance techniques 
that enable the 3D structures of entire proteins to be identified and recorded into a 
computer database, computational methods can identify the essential features 
required for activity by analyzing existing drug target binders and using this 
information to prioritize compounds for in vitro testing. This will help to improve 
the hit rate of HTS and to form better prediction models to improve safety profile 
of drugs, thereby reducing the cost of finding novel inhibitors or making useful 
lead modifications to existing drugs or chemical compounds. 
 
There are two main approaches for computer-based methods: ligand-based 
and structure-based. Ligand-based methods can be used when there are at least a 
certain number of active and inactive compounds against a biological target. 
These compounds are used to derive a quantitative structure-activity relationship 
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(QSAR) model or a pharmacophore model, which can then be used for virtual 
screening of large chemical libraries for potential active compounds. 
 
In structure-based methods, molecular docking and molecular modeling 
which includes building homology models, screening with target-based 
pharmacophore models and molecular dynamics simulations are used to dock and 
refine the binding orientation of the compound. A method to improve the 
screening efficiency of structure-based methods is to use a ligand-based method 
to perform a preliminary screening of large chemical libraries and reduce the list 
of potential inhibitors to a more manageable number for structure-based 
studies[87-92]. 
 
1.5.1 Ligand-based methods 
 
Quantitative structure-activity relationship (QSAR) 
   
The QSAR approach attempts to identify and quantify various properties 
of different compounds using 1D, 2D, 3D chemical descriptors or fingerprints of 
the compounds to see whether any of these properties have any effect on 
biological activity. The underlying assumption in QSAR is that similar molecules 
should exhibit similar binding properties with respect to a given target. If there is 
a relationship or correlation between any of the descriptors and the compound’s 
biological activity, an equation can be drawn up to quantify the relationship and 
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hence allow some level of prediction to be made for the biological activity of a 
new and structurally different drug compound within a chemical library or a 
related analogue. Since the first QSAR model was published[93], it have been 
used routinely in the early stages of drug design to screen large chemical libraries 
prior to in vitro testing. QSAR has the advantage of being able to screen through 
large chemical libraries very rapidly as it only looks for desirable 1D, 2D, 3D 
descriptors and structural fingerprints of compounds that have been reported in 
the literature to be a positive or negative compound. However, this method is not 
able to determine the binding conformation of the compound in the target site. 
 
Ligand-based pharmacophore modeling 
 
Ligand-based pharmacophore modeling is typically performed by 
extracting common chemical features from 3-dimensional structures of known 
ligands which show essential ligand-macromolecule interactions[94]. The 
common chemical features or pharmacophore elements that are usually used as 
types of the desired interactions are hydrogen-bond interactions, hydrophobic 
interactions and ionic interactions. A pharmacophore is based on the concept of 
similarity between ligands and is used in virtual screening to explore diverse 
chemical compounds in large chemical databases for the purpose of identifying 




Current studies using ligand-based methods for JNK inhibitors and PXR 
activators 
 
Ligand-based approaches have been used to develop 2-dimensional (2D) 
and 3-dimensional (3D) QSAR models for JNK inhibitors[95-98]. The models 
were used to propose modifications for improving the inhibitory activities of 
existing JNK inhibitors. There are several QSAR models that have been built on 
compounds that target the ATP-binding site, with an overall prediction accuracy 
that is greater than 90%[95], a Matthew’s Correlation Coefficient that is greater 
than 0.7[96], a conventional or cross-validated r2 that is greater than 0.9[97,98]. 
The disadvantage in using these models are that they are used on compounds 
which target the ATP binding site, which may lead to potential selectivity and 
specificity problems. There is currently no QSAR model for inhibitors that bind to 
the JIP binding pocket. 
  
Ligand-based approaches that have been used to predict human PXR 









1.5.2 Structure-based methods 
 
Target-based pharmacophore modeling 
  
Today, structure-based methods in pharmacophore modeling have gained 
significant interest in the past 5 years due to the increase in number of protein-
ligand crystal structures. 3D pharmacophore modeling is a well-established in 
silico technique which provide benefits for early drug design. Pharmacophore 
models visualize chemical features that are supposed to be important for protein-
ligand interactions and therefore for biological activity. They aim to be 
complementary to docking procedures, by providing information on possible 
docked poses and require less computational resources than random docking 




 Docking is a structure-based method where computer software is used to 
assess the complementarity of a ligand to a defined binding site on the drug target. 
The docking program attempts to explore and obtain binding orientations and 





Docking may also include calculation of all possible binding interactions 
that may occur within the ligand itself or specified amino acid residues within the 
entire protein, binding interactions between the ligand and the amino acid residues 
within the defined binding site and binding interactions between ligand or amino 
acid residues with X-ray crystallographic or free solvent molecules. Docking may 
also include optimization of the fit between the ligand and the defined binding site 
by modeling flexibility of the surrounding amino acid residues within the defined 
binding pocket and modeling movements of the ligand and solvent molecules 
within the docked pose. 
 
Simpler methods of docking involve overlaying possible ligand 
conformers onto solvent accessible surfaces or Connolly surfaces within the 
defined binding pocket without calculating any possible steric clashes or binding 
interactions. More advanced and computationally demanding methods of docking 
involve finding as many possible poses of the ligand that is predicted to occur 
within the defined binding site and is assigned a docking score to each predicted 
pose that is parameterized using data derived from published X-ray structures. 
This scoring function is derived by assigning a certain number of weights and 
penalties to various different factors that are visible from the experimentally 
determined structures and uses this mathematical model to rank and predict the 
docked compound and its pose as having strong, weak or no binding affinity as a 




There are two problems associated with molecular docking used in 
structure-based approaches. The first is the identification of accurate poses of the 
ligand in the active site of the protein. Generally, proteins with larger active sites, 
flexible and poorly defined binding sites due to hinge region and chemical 
compounds with a greater number of single bonds that are rotatable are more 
likely to lead to multiple predicted binding modes. This may lead to false 
predictions during virtual screening due to the compound having multiple 
favourable interaction profiles and multiple highly ranked poses. 
 
Another problem is the assigned rank and docking score of compounds 
often have a poor correlation with the actual biological activity of the compound. 
This is due to multiple factors such as the simplistic sampling methods which are 
often based on a rigid frozen snapshot of the entire protein molecule and its active 
site, the use of an empirical scoring function, desolvation, conformational energy 
penalties, choice of force fields being used and removal of solvent molecules that 
may play an important role in the binding of the compound[102-105]. 
 
Molecular dynamics (MD) 
 
Molecular dynamics simulations, in which entire protein-ligand systems 
are allowed to interact for a period of time based on Newton’s equations of 
motion, are widely used computational techniques for the study of protein 
macromolecules and small chemical compounds in solvent medium[106,107]. 
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MD is very useful for understanding the dynamic behavior of the entire protein-
ligand system that is modeled in a solvent medium at a certain temperature and 
pressure, which include internal motions, conformational changes or even protein-
folding processes. Due to limitations from virtual screening methods in docking 
and pharmacophore modeling where the ranking correlation of the compounds 
with published biological activity is poor and inaccurate, molecular dynamics is 
carried out after docking with pharmacophore constraints where the reduced 
number of poses for each compound is more manageable for the molecular 
dynamics study. 
 
 The results from MD simulations can be used to refine models of protein-
ligand systems obtained from docking. Such simulations display flexibility of the 
entire model of the protein-ligand system, and show its relative duration and 
likelihood of binding interactions with respect to time and thus coming closer to 
modeling induced-fit effects more accurately. Incorrectly docked structures and 
poses generated from docking have a higher chance of generating unstable MD 
trajectories leading to the disruption of the complex, which provides an additional 
mechanism to filter for false positives. MD simulations usually include explicit 
solvent molecules-often water with salts as counterions within the model, which is 
very important to understand the role of the particular solvent and its effect on the 
stability of the protein-ligand complexes[88]. In this research project, MD 




Current studies using structure-based methods for JNK inhibitors and PXR 
activators 
 
Structure-based approaches are currently used on reported JNK inhibitors 
that bind strongly to JNK after HTS is carried out[65,81-84], and in virtual 
screening of chemical databases[108]. The models are used to explain the binding 
pose and the type of binding interactions that occur between the compound and 
the enzyme. These approaches test a very small subset of compounds from 
chemical databases, hence there is a knowledge gap in identifying JNK inhibitors 
where there is room for novelty by having a less saturated chemical space to 
explore. 
   
There are 9 available X-ray crystal structures of human PXR[75,86,109-
113] and due to the highly flexible nature of the ligand-binding domain in human 
PXR[75,111,112,114], as well as the capacity of the nuclear receptor to bind to a 
very large variety of different chemical compounds of various molecular weights, 











1.6.1 Objective 1: Identify potent JNK inhibitors that target JIP binding 
site and DFG binding site 
 
In this project, the JIP binding site and DFG binding site were selected as 
the target sites for designing potent JNK inhibitors. The JIP binding site was 
selected because there are known inhibitors that target this site and this will 
facilitate the development of a QSAR model for screening large chemical 
libraries[119]. This will reduce the number of compounds that need to be 
screened using structure-based drug design.  A search through patent databases 
also revealed entire protein macromolecules as the only registered patents that 
target the JIP active site. The DFG binding site was selected because there is only 
one compound that is known to bind to this site currently. Thus there is great 
potential to discover novel potent inhibitors that target these two sites. 
 
The ATP binding site was not selected because of the following reasons. 
Firstly, there are more than 900 compounds that have been published to bind at 
this site, with many new inhibitors being discovered and published every year. 
Thus, there is less novelty for such inhibitors. Secondly, the ATP site is highly 
conserved and is present in many other protein kinases. These factors reduce the 
appeal of discovering novel inhibitors that bind at this site. For these reasons, 
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designing ATP-competitive inhibitors are less attractive and will not be carried 
out in the project[120]. 
 
JNK inhibitors targeting the JIP binding site 
  
This project aims to fill the current research gap by developing a QSAR 
model for the JIP binding site. The QSAR model will address the issue of having 
a limited diversity in the dataset by including an additional 1228 compounds from 
the FDA Orange Book as putative negative compounds to train the QSAR model. 
This QSAR model will also include an additional algorithm that will define 
multiple thresholds for positive and negative compounds to automatically reject 
compounds for which the computational model is not able to make a prediction 
with a certain degree of confidence. This will define the applicability domain of 
the model to ensure that it is not used inappropriately. This QSAR model will also 
include external five-fold cross validation to validate the model more rigorously 
and include a DivEnsemble algorithm to select models to use in each consensus 
model. 
 
In this research project, a QSAR model will be developed to screen the 
ZINC chemical library and used in combination with structure-based methods to 





JNK inhibitors targeting the DFG binding site 
 
Currently, there is only one compound known to bind to the DFG binding 
site of JNK2 and p38α. Therefore, there is a large gap in this area. The Type II 
mechanism of inhibition at this active site suggests that inhibitors that target this 
binding site would also be less likely to inhibit other kinase enzymes. Therefore, 
the significance of this objective is that new compound classes that target this site 
could be discovered.  
 
In this research project, docking will be carried out to screen the ZINC 
chemical library to identify inhibitors that target the DFG binding site of JNK2. 
Identified compounds would be tested for biological activity by determining their 
dissociation constant values on two JNK isoforms and one p38 subtype. 
 
1.6.2 Objective 2: Form an in silico model for human and zebrafish PXR 
activators 
 
Since PXR was discovered, there are studies to determine the type of 
compounds that can bind and exert an agonist, antagonist or partial agonist effect 
on the receptor[74,76,77,121]. This is because PXR have been shown to regulate 
several genes which encode drug-metabolizing enzymes and drug 
transporters[23]. Hence, there is interest in studying the mechanism of binding 
and activation in detail as this nuclear receptor may provide valuable insights into 
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the possible metabolism and removal of various xenobiotics including various 
drugs and environmental toxins. 
 
 In order to study the biological effect of various approved drugs on PXR 
activation, the expression of the gene Cytochrome P-450 (CYP)3A4 was chosen 
as the marker to investigate the amount of biological activity and PXR activation 
by collaborators at University of British Columbia at Vancouver and NUS.  This 
is because CYP3A4 gene expression was shown to be upregulated upon PXR 
activation[122-125]. CYP3A4 gene expression levels are obtained from 
Firefly/Renilla luciferase assay on human liver cells or from in vivo study on 
zebrafish Danio rerio as it is able to perform a high-throughput screen compared 
to other larger animal models, less expensive to perform a study on and takes a 
relatively shorter time to obtain results. 
 
 This study will attempt to investigate the mechanism of binding of various 
approved drugs on the ligand-binding domain (LBD) of human PXR and 
zebrafish PXR, attempt to correlate its degree of binding with the selected marker 
for biological activity and attempt to improve on existing structure-based and 
molecular modeling methods to obtain a better correlation.  
 
 There is currently a knowledge gap in this area where there are no 
available 3D structures of zebrafish PXR and there are no structure-based models 
that can correlate zebrafish PXR activity with human PXR activity in the 
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literature. The significance of this objective is that developing a structure-based 
model to predict PXR activity and CYP3A4 gene expression more accurately in 
human and zebrafish will help to reduce time and costs involved with assays 
which use human liver cells. In addition to availability of biological activity data 
on 14 approved drugs and 1 chemical compound from collaborators, there are 
site-directed mutagenesis studies on the ligand-binding domain of human PXR in 
the literature which could help to elucidate the mechanism of binding of various 
ligands in the X-ray crystal structure of human PXR and the homology model of 
zebrafish PXR[85,86,112]. All these factors make the development of structure-
based models for human and zebrafish PXR activity attractive.   
 
As rifampicin was chosen as the positive validation compound and it was 
found to show differences in CYP3A4 gene expression in human and 
zebrafish[126], the study of PXR agonist activity in both human and zebrafish 
PXR will be carried out first in this project. There are also fewer biological 
activity data on zebrafish in the literature and ligand-based methods to investigate 















 A truncated form of JNK interacting protein 1 (JIP1) consisting of 11 
residues 153-163  (RPKRPTTLNLF) has been found to inhibit JNK1 by reducing 
the amount of space for ATP to bind to JNK1[57,60]. A dataset of 191 positive 
and negative compounds are obtained from published sources and are used to 
build a QSAR model. Building a QSAR model has its advantages in the early 
stages of screening large chemical libraries when 3D structural information of the 
protein system is not required, and the model when trained using putative 
negative compounds to augment the dataset, helps to increase its applicability 
domain and is more likely to make more accurate predictions and predict more 
compounds that may be structurally diverse. This QSAR model is then applied on 
the ZINC chemical library to identify a set of compounds that could potentially 












A total of 191 compounds and their reported IC₅₀ in a LanthaScreen™, 
AlphaScreen™ or kinase assay test for JNK1 inhibition (JIP site binders, Dual-
action ATP-JIP site binders) were collected from published studies[37,62,81-
84,127]. The compounds were then categorized into positive (JNK inhibitors) and 
negative (JNK non-inhibitors) compounds using a cutoff value of IC₅₀ at 10 µM. 
 
A single cutoff value was chosen because a binary classification model 
will have problems in predicting compounds that have biological activity that lie 
between two different IC₅₀ cutoff values where most models do not have a valid 
prediction option to classify these compounds.  Also, if these compounds were 
removed and not included in the dataset, it would reduce the number of 
compounds in the training set to train the model and might potentially impact the 
performance of the model.  
  
An additional 1228 compounds from FDA Orange Book which were not 
known to inhibit JNK1 were added to the total dataset as putative negative 
compounds because this had been shown to reduce the number of false 
positives[128].  The total dataset of 1418 compounds were split into the training 
set data and external validation set data by a stratified sampling method in an 80 
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to 20 ratio to ensure that the number of positive compounds and negative 
compounds were adequately represented in both datasets. The training set was 
used to develop the QSAR model. The validation set was used to evaluate the 
performance of the QSAR model and was not used during the development of the 
model. To rigorously validate the final consensus model, we adopted the 
recommended rigorous validation approach[129]. This is done by repeating the 
entire model development process five times using different training and 
validation sets. The following flowchart in Figure 2.1 describes the gathering and 






















Stratified sampling method 20:20:20:20:20 ratio 
 















Figure 2.1: Flowchart of steps taken to obtain the training and validation set. 
Collected JNK1 inhibitors 




87 positives, 1332 negatives 
Training set 1 
(Subsets A,B,C,D) 






















Training set 6  
(Subsets A,B,C,D,E) 
87 positives,  
1332 negatives 
Validation set 1 
(Subset E) 
17 positives, 266 
negatives 
Training set 2 
(Subsets A,B,C,E) 
70 positives, 1066 
negatives 
Training set 3 
(Subsets A,B,D,E) 
69 positives, 1066 
negatives 
Training set 4 
(Subsets A,C,D,E) 
69 positives, 1065 
negatives 
Training set 5 
(Subsets B,C,D,E) 
70 positives, 1065 
negatives 
Validation set 2 
(Subset D) 
17 positives, 266 
negatives 
Validation set 3 
(Subset C) 
18 positives, 266 
negatives 
Validation set 4 
(Subset B) 
18 positives, 267 
negatives 
Validation set 5 
(Subset A) 




2.2.2 Calculation of descriptors 
 
All the compounds were drawn using ChemDraw Pro 12.0[130]. A total of 
729 1D and 2D descriptors were calculated by PaDEL-Descriptor 2.12[131]. 3D 
descriptors were not included in the calculation because in some previous QSAR 
studies, it has been shown that including 3D descriptors in a QSAR model did not 
necessarily improve the performance and prediction ability of such a QSAR 
model[132,133]. The descriptors were normalized using range transformation to a 
maximum value of 1 and a minimum value of 0. This is to ensure that all 
descriptors have equal potential to affect the QSAR model. 
 
Irrelevant descriptors, such as constant descriptors were removed. Genetic 
algorithm (GA) was then used to remove the remaining irrelevant and redundant 
descriptors. A population size of 50 and number of generations of 100 was used 
for the GA descriptor selection process. During the GA descriptor selection 
process, QSAR models developed using different descriptor subsets were 
evaluated using five-fold cross-validation. The GA descriptor selection was 
repeated 30 times for each modeling method to generate 30 QSAR models for 







2.2.3 QSAR model development 
 
Two different modeling methods, Naïve Bayes (NB) [134,135] and 
support vector machine (SVM) [136,137]were used to develop the QSAR models. 
For SVM, the cost value is kept constant at a high value of 100000 to simulate a 
hard-margin SVM. The Gaussian radial basis function kernel, which is commonly 
used for QSAR studies, was used as the kernel function in this study since it is 
able to handle non-linear relationships between class labels and descriptor values. 
The optimum γ value was determined by experimenting with the empirical value 
of 1 divided by the number of examples in the training set and 2-5, 2-7, 2-9…….2-15. 
 
2.2.4 Defining the applicability domain with multiple thresholds 
  
An important aspect of QSAR modeling is the definition of a domain of 
applicability for the model. In this study, we adopted the multiple threshold 
algorithm proposed by Fumera et al[138] to define the applicability domain for 
the QSAR models.  
  
The algorithm uses a binary class-related reject threshold (CRT) rule 
where for a classification task with N data classes that are characterized by 









k = 1, …, N  P(ωk | x) = P(ωk | x) < Ti  (1) 
 





k = 1, …, N  P(ωk | x) = P(ωk | x) ≥ Ti  (2) 
 
The CRTs take on values in the range [0,1].  The determination of the 
optimum threshold values was determined by minimizing the theoretical accuracy 
of the rejected compounds based on five-fold cross-validation[139,140]. 
 
2.2.5 Consensus model 
  
Consensus modeling is carried out to build the final QSAR model. This is 
to enable the many different models, each with similar measures of performance, 
but different set of descriptors, to be used as an ensemble classifier to better 
predict unknown compounds during the actual screening process and to take into 
account random variations in each base model that might have certain descriptors 
being used, and other descriptors being left out of the model building process. 
This will help to improve the classification accuracy[141,142]. In this study, five 
models were selected using a DivEnsemble method to obtain the optimum 
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classification performance[139]. A compound is considered to be within the 
applicability domain of the consensus model if at least one base model considered 
the compound to be within its applicability domain and there are no ties in the 
predictions. 
 
2.2.6 QSAR model validation 
 
The performance of the QSAR models in the GA descriptor selection 
process were assessed by computing true positives (TP), true negatives (TN), 
false positives (FP) and false negatives (FN) from the cross-validated models, 
which were then used to calculate the Matthew’s Correlation Coefficient (MCC) 
= 
TP × TN –FN ×FP
√(TP+FN)(TP+FP)(TN+FN)(TN+FP)
. The MCC value was used to compare the 
performance of the models developed using different descriptor subsets and to 
identify best descriptor subset for each GA descriptor selection run. 
 
The consensus model developed using five selected performing models 
was assessed using the rigorous validation approach. Other than MCC, the 
sensitivity (SE) = 
TP
TP+FN
 x 100%  , specificity (SP) = 
TN
TN+FP
 x 100%  , overall 
prediction accuracy (Q) =  
TP+TN
TP+TN+FP+FN
 x 100%  and Geometric mean (GM) = 





2.3 Results and discussion 
 
2.3.1 Validation of the consensus model 
 
The consensus model was formed from three SVM models and two NB 
models. The performance of the consensus model assessed using the rigorous 
validation approach are shown in Table 2.1. 
Table 2.1: Performance of consensus model on each validation set and on the 
entire dataset. 
 
Dataset TP FP TN FN Outside 
AD 
SE SP Q GM MCC 
Validation 
set 1 
9 3 260 5 3 positive, 
3 negative 
0.643 0.989 0.971 0.797 0.680 
Validation 
set 2 
11 6 260 5 1 positive 0.688 0.977 0.961 0.820 0.646 
Validation 
set 3 
9 8 249 6 3 positive, 
9 negative 
0.600 0.969 0.949 0.763 0.537 
Validation 
set 4 
9 9 256 5 4 positive, 
2 negative 
0.643 0.966 0.950 0.788 0.541 
Validation 
set 5 
10 3 263 3 4 positive, 
1 negative 
0.769 0.989 0.979 0.872 0.758 
Average N/A N/A N/A N/A N/A 0.669 0.978 0.962 0.808 0.632 
Entire 
dataset 
74 10 1319 11 2 positive, 
3 negative 
0.871 0.993 0.985 0.930 0.868 
 
None of the 10 false positives were from the putative negative dataset. 
Although this may suggest that the consensus model may just be differentiating 
between the compounds with IC50 values and putative negatives rather than 
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learning the actual difference between positive and negative compounds, we do 
not believe this is true. This is because the 10 false positives were just 
approximately 10% of the total true negatives. Thus the majority of true negatives 
were still accurately predicted by the model. In addition, as we will show using 
structural similarity and distribution below, when the consensus model was used 
on a large chemical library, the predicted actives include compounds that were 
structurally different from the positive training compounds. This suggests that the 
model is truly discriminating between positive and negative compound and not 
merely discriminating between compounds with IC50 values and putative 
negatives. Among the false negatives, they have IC₅₀ values of between 0.4 µM 
and 10 µM. This indicates that the false negative predictions are mainly due to the 
compounds being difficult to classify as positive or negative compounds due to 
their IC₅₀ values that are near to the defined threshold cutoff values. 
 
2.3.2 Screening of ZINC chemical library using QSAR model 
 
 The results from using the consensus model to screen the ZINC chemical 











Table 2.2: Virtual screening of ZINC library using consensus model. 
Numbers in parenthesis refer to the percentage of compounds in 
their respective columns to the total number of compounds in the 
ZINC chemical library. 
 













17833934 (100.0) 45673 (0.256) 17409760 (97.622) 378501 (2.122) 
 
The number of identified potential JIP1-binding inhibitors is manageable 
for the subsequent docking study. 
 
2.3.3 Structural similarity and distribution 
 
Structural similarity of the compounds in the dataset and in the ZINC 
compound database is calculated by a fingerprint, FP2 in Open Babel[145]. The 
fingerprints of positive compounds in the dataset, is compared to other 
compounds by using the Tanimoto coefficient, the number of bits in common 
divided by the union of the bits set. 
 
 The data set is more diverse when the diversity index, which is the average 
value of the Tanimoto coefficients between pairs of compounds in the dataset, 
approaches 0. Table 2.3 below lists the Tanimoto coefficients and diversity index 
of each list of compounds. 
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Table 2.3: Structural diversity of compounds. 
 







JIP site compounds 
(n = 191) 
0.0975 0.892 0.334 
JIP site compounds 
and putative 
negatives 
(n = 1318) 
0.0065 0.355 0.136 
ZINC compounds 
picked out as hits 
(n = 45673) 
0.0223 0.792 0.201 
  
 The average lowest pairwise Tanimoto coefficient for the ZINC 
compounds that were identified as potential actives compared with all the positive 
compounds used in training the model was 0.0223. This suggests that our 
consensus model presented in this work is able to identify novel potential 
inhibitors that are structurally different from currently known inhibitors. Three of 







Table 2.4: A selection of ZINC compounds not reported as JNK inhibitors 






















2.3.4 Molecular descriptors 
 
 A total of 168 descriptors, which are listed in Table 2.5, were included in 
the consensus model to screen through the ZINC chemical library. Details of the 
descriptors can be found in the journal article for PaDEL-Descriptor[131]. 
 
 Statistical analysis of the molecular descriptors between inhibitors and 
non-inhibitors showed that 17 descriptors had statistically significant different 
mean values between inhibitors and non-inhibitors. Inhibitors have higher values 
in terms of hydrogen-bond donors and acceptors, and internal hydrogen bonds 
(nHBd, SHBa, nHBint4 and minHBInt6), molecular electrotopological variation 
(DELS), electronegativity of the extended topochemical atom (ETA_Epsilon_2) 
and Petitjean Number. On the other hand, non-inhibitors have higher Ghose-
Crippen molar refractivity (AMR), Broto-Moreau autocorrelation of the 
topological structure weighted by polarizability (ATSp1 and ATSp3), valence chi 
path cluster (VPC-6), valence chi path (VP-3), sum of weak hydrogen bond 
acceptors (SwHBa), sum of the electronic state of aromatic bonds attached to a 
CH group (SaaCH), sum of the alpha values of all non-hydrogen vertices that is 
connected to only one other non-hydrogen vertex(ETA_AlphaP) and number of 
six-membered rings (n6Ring and nT6Ring)[146-151]. Some of these features are 







Table 2.5: Descriptors used in the consensus model. 
 
Descriptor type Number Descriptor 
ALOGP 1 AMR 
APol 1 apol 
Atom count 5 nAtom, nHeavyAtom, nF, nP, nI 
Autocorrelation 
(polarizability) 
3 ATSp1, ATSp3, ATSp5 
BCUT 2 BCUTc-1l, BCUTp-1h 
Bond count 1 nBondsD2 
Bpol 1 bpol 
Carbon types 3 C2SP2, C3SP2, C4SP3 
Chi chain 2 VCH-3, VCH-5 
Chi path cluster 3 VPC-4, VPC-5, VPC-6 
Chi path 7 SP-0, SP-3, SP-4, SP-6, VP-0, VP-1, VP-3 






91 nHBd, nwHBd, nwHBa, nHBint4, nHBint5, nHBint7, nHsSH, nHssNH2p, 
nHsssNHp, nHdCH2, nHdsCH, nHCHnX, nHAvin, nsCH3, ndsCH, ndssC, 
naasC, nssssC, nsNH3p, nssNH2p, ndNH, nssNH, ntN, nsssN, nsOH, 
nsOm, nsSH, nsBr, SHBa, SwHBa, SHBint2, SHBint7, SHBint8, SHdNH, 
SHssNH, SHsNH3p, SHdsCH, SHCHnX, SHCsats, SHother, SaaCH, StN, 
SdsN, SsssN, SaasN, SdO, SssO, SdS, SaaS, minHBa, minHBint4, 
minHBint6, minHsOH, minHsNH3p, minHsssNHp, minHtCH, minHdsCH, 
minHAvin, mintCH, mindsCH, mindssC, minsNH2, minssNH2p, 
minaaNH, mintN, minsssNHp, minssO, minsOm, minsF, minsSH, mindS, 
maxHBa, maxHBint8, maxHdNH, maxHsSH, maxHssNH, maxHaaNH, 
maxHtCH, maxHAvin, maxtCH, maxsNH2, maxdNH, maxtN, maxssssNp, 




15 ETA_Alpha, ETA_AlphaP, ETA_Epsilon_1, ETA_Epsilon_2, 
ETA_Epsilon_3, ETA_Epsilon_5, ETA_dEpsilon_B, ETA_Shape_P, 








Largest chain 1 nAtomLC 











5 MLFER_BH, MLFER_BO, MLFER_E, MLFER_L 
Petitjean number 1 PetitjeanNumber 
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Ring count 10 n3Ring, n6Ring, nG12Ring, nF7Ring, nF8Ring, nT5Ring, nT6Ring, 
nT7Ring, nT8Ring, nT12Ring 
Weighted path 3 WTPT-1,WTPT-2, WTPT-5 




 From a dataset of 191 JNK1-JIP1 binding site inhibitors and non-
inhibitors and 1228 putative negative compounds, a consensus model that consists 
of three SVM models and two NB models was developed. This consensus model 
was used to screen the ZINC chemical library that contains 17833934 different 
compounds. A total of 45673 compounds were identified as positive compounds 
based on the consensus model. The identified positive compounds have a high 
degree of diversity from the tested positive compounds and hence there is more 
potential to identify novel compounds that are structurally different from tested 
compounds. The next phase of the research project will use structure-based 


















 The truncated form of JNK interacting protein 1(JIP1) has been found to 
inhibit JNK1 by reducing the amount of space for ATP to bind to JNK1[57,60]. A 
dataset of 45673 ZINC database compounds have been identified by the QSAR 
model to be possible inhibitors that target this binding site. The model is then 
refined using structure-based methods which include docking, pharmacophore 




3.2.1 Preparation of JNK1 structure 
  
The X-ray crystal structure of JNK1 together with the truncated version of 
JIP1 which was discovered to be necessary for inhibition of JNK1 by Barr et 
al[60] was available in the RCSB Protein Databank by Heo et al(PDB ID: 
1UKH)[56,57]. Figures 3.1 and 3.2 show JIP1 in complex with JNK1. The JNK1 
structure was preprocessed by using the structure preparation wizard which 
45 
 
includes adding hydrogen atoms to the entire protein, assigning a cap at the 
terminal ends of the protein and assigning protons to the entire structure[152]. 
From the X-ray crystal structure, the following residues are thought to be 
important in binding and inhibitory activity: Arg 127 and Glu 329. 
 
Figure 3.1: Ribbon structure of JNK1 with truncated JIP1 (PDB ID: 1UKH). 
 
Fig 3.2: Close-up of truncated JIP1 in binding pocket of JNK1. Residues of 
JIP1 are labelled. 
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The JIP1 binding site consists of 9 hydrophobic residues (Ala 113, Leu 
115, Val 118, Met 121, Leu 123, Leu 131, Val 159, Val 323 and Trp 324), 3 polar 
residues (Tyr 130, Ser 161 and Cys 163) and 3 polar and charged residues (Glu 
126, Arg 127 and Glu 329) (Figures 3.3 and 3.4).  
 
3.2.2 Virtual screening for potential JNK1-JIP1 inhibitors  
 
Virtual screening of the 45673 compounds identified by the QSAR model 
was carried out using rigid docking methods in MOE 2012.10. A pharmacophore 
model was developed using MOE 2012.10[153] to improve the quality of the 
docked poses. Three interactions were chosen to include in the pharmacophore 
model in Table 3.1 and Figure 3.3. 
Table 3.1: List of pharmacophore points selected in model. 
 
Name of residue(s) in 
JNK1 
Name of residue in 
JIP1 
Type of interaction 
Arg 127 Thr 159 Hydrogen bond 
Ser 161 Leu 160 Hydrogen bond 
Val 118,  Leu 123, Leu 
131, Val 159, Cys 163 






Figure 3.3: Pharmacophore model developed using MOE 2012.10. JIP1 is 
displayed as a stick diagram, JNK1 is displayed as a line diagram. 
Residues are labelled. Hydrogen bond donor and acceptor 
interactions are shown as magenta and cyan spheres respectively, 
and hydrophobic interactions are shown as green spheres. Carbon 
atoms are coloured orange or white, nitrogen atoms are coloured 
blue and oxygen atoms are coloured red. 
 
 
During docking, energy minimization of the protein and ligand structures 
was carried out using the AMBER99 forcefield at a gradient of 0.1 
kcal/mol/Å[154]. The Triangle Matcher ligand placement[155], London dG 
scoring function, refinement using AMBER99 forcefield and Generalised Born 
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Volume Integral / Weighted Surface Area (GBVI/WSA) dG rescoring function 
were used in this docking with pharmacophore constraints process[156-158]. 
 
 Molecular dynamics simulations were carried out on selected poses which 
fit alongside the JIP1 binding groove of JNK1, fit the pharmacophore model and 
had the best docking energy score. All topology and parameter files were created 
using the LEaP program included with AMBER. The entire system to be 
simulated consists of the protein surrounded by a truncated octahedron of water 
and sodium ions to maintain charge neutrality. An explicit solvent model was 
used with TIP3P water molecules filling 12.0 Å between the surface of the protein 
and the edge of the box[159]. 
 
The SANDER package within AMBER was used for 1000 steps of 
restrained energy minimization and non-restrained energy minimization. The 
amino acid residues which make up JNK1 were restrained in the first energy 
minimization process. In both energy minimization processes, steepest descent 
minimization was used for the first 500 steps. After 500 steps, the energy 
minimization process is switched to conjugate gradient. The PMEMD module 
from Amber 12.0[160] was then used to model the system to equilibrium by 
including 100 ps of constant volume conditions with heating from 0 to 310 K and 
positional restraints, followed by 100 ps at constant temperature conditions to 
maintain the density at equilibrium before beginning the molecular dynamics 
production run with the NPT ensemble. The MD simulations were carried out 
49 
 
with a 2 fs time step using the AMBER 2003 force field[161]. Hydrogen bonds 
were constrained using the SHAKE algorithm[162]. Each molecular dynamics 
production run has a total duration of 3 ns with a time step of 10 ps for every 
frame recorded in its trajectory. 
 
Viewing of the trajectories and clustering of a trajectory was carried out 
using Chimera 1.8[163]. The CPPTRAJ module in Amber 12.0 was also used to 
carry out postprocessing of the trajectory which includes calculating the ligand 
root mean square deviation (RMSD) and an alternative hierarchical agglomerative 
clustering of the trajectory. Trajectories which show a large RMSD value where 
the bound ligand keeps changing conformation throughout the trajectory, moved 
out of the binding pocket or formed many clusters of very small and different 
populations were determined to have an unstable trajectory and the compound 
was removed from the dataset based on this additional filter. Trajectories which 
showed a relatively stable trajectory by remaining within the binding pocket with 
little change in conformation and hence low ligand RMSD values and the most 
populated cluster having the largest population compared to other clusters within 
the trajectory were retained for further analysis.  
 
A redocking experiment was carried out using rigid docking methods in 
MOE 2013.10 where poses with interactions that are consistent with the 
molecular dynamics trajectory data are chosen. The ligand pose is energy 
minimized using the MMFF94 force field[164] and the electrostatics, polar and 
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hydrophobic contact surfaces surrounding the ligand pose are analysed using the 
surface analysis feature in MOE[165]. 
 
3.2.3 Analysis of interaction profiles of identified JNK1-JIP1 inhibitors 
  
After refining the list of compounds based on the results of the ligand-
based and the structure-based studies, the list of compounds were further refined 
for further analysis by identifying poses which meet the pharmacophore 
modeling, molecular dynamics simulations and redocking criteria: 
1) The compound fits into the binding pocket that JIP1 occupies in the X-ray 
crystal structure of JNK1. 
2) The compound forms an electrostatic or polar interaction with Arg 127. 
3) The compound forms hydrophobic non-bonded contacts with Val 118, Leu 
123, Leu 131 and Val 159. 
 
MGLTools[166], Ligplot[167], Discovery Studio Visualizer[55] and MOE 
were used to visually inspect selected binding pose on the protein target and the 
interactions that were formed. Chimera 1.8 was used to analyze each trajectory, 
calculate the root mean-square deviation (RMSD) of the ligand and to carry out 
clustering of the entire trajectory to select representative poses from the most 
populated cluster[163]. The CPPTRAJ module in Amber 12.0 was used to 
monitor the distance between a ligand atom and a residue atom where hydrogen 
bond could potentially be present. If pi interactions could potentially be present, 
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the distance between the geometric center of the aromatic ring of the ligand and 
the residue atom was monitored.  
  
3.3 Results and Discussion 
 
3.3.1 Initial virtual screening using docking with pharmacophore 
constraints 
 
 The structure 1UKH which contains the truncated JIP1 in complex with 
JNK1 was used to obtain and select pharmacophore features. A less strict criteria 
was chosen for the pharmacophore map where the H-bond interaction with Arg 
127 and the non-bonded contact with Cys 163 was chosen to enable a subset of 
the tested JNK1 inhibitors in the literature to meet this docking with 
pharmacophore constraints criteria. The results are briefly summarized in the 
Table 3.2. 













BI-78D3 18922779 0.28 Yes 0 - 
No 26 9.13 to -4.59 
25 21458276 1.3 Yes 5 -3.96 to -4.65 
No 20 -0.37 to -4.42 
19 21458276 1.8 Yes 2 -4.01 to -4.29 
No 23 -2.93 to -4.26 
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BI-98A10 20045647 3.0 Yes 3 -3.12 to -3.78 
No 24 7.09 to -4.29 
1 19243309 3.6 Yes 0 - 
No 28 3.36 to -5.06  
87D12 19282190 3.8 Yes 0 - 
No 19 3.80 to -3.82 
BI-90H10 20045647 5.7 Yes 0 - 
No 27 8.82 to -4.72 
 
BI-90H8 20045647 9.1 Yes 0 - 
No 24 -0.53 to -4.75 
AV-7 19527717 10.0 Yes 0 - 
No 30 3.26 to -4.92 
BI-90E2 20045647 > 25 Yes 3 -3.88 to -4.46 
No 24 6.52 to -4.56 
BI-90E7 20045647 > 25 Yes 4 -3.76 to -4.73 
No 25 8.70 to -4.18 
BI-83B3 18922779 > 100 Yes 0 - 
No 19 2.39 to -4.24 
8e 19271755 > 100 Yes 0 - 
No 28 13.34 to -4.70 
3 21458276 > 100 Yes 2 -3.45 to -3.64 
No 26 4.97 to -4.45 
5a 21458276 > 100 Yes 1 -4.27 
No 28 -2.88 to -4.35 
10 21458276 > 100 Yes 2 -3.86 to -4.28 
No 22 2.82 to -4.07 
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The results from the rigid docking of compounds show a large number of 
different predicted poses and a wide range of docked scores with a molecular 
mechanics generalized born/volume integral (MM/GBVI) binding free energy, 
with some poses having a calculated binding energy that is in the positive range 
and is less likely to bind and form interactions when the pharmacophore 
constraints filter was not used.  
 
Including this pharmacophore constraints filter reduced the number of 
docked poses for each compound from 30 to 5 or less. This suggests that the 
pharmacophore constraints filter is potentially able to remove erroneous poses. 
 
 The docking process was repeated using the same pharmacophore filter on 
identified positive compounds from the QSAR model in Chapter 2 and reduced 
the number of possible compounds from 45673 to 17560. This additional step 
helps to reduce the time needed to dock each compound, and also helps to further 
refine and reduce the number of docked poses for molecular dynamics studies, as 
each molecular dynamics simulation run can take a very long time to complete 
and the starting pose of a compound appears to have an important role in 







3.3.2 Refinement of virtual screening using molecular dynamics 
 
 Molecular dynamics using the software package AMBER 12.0 was carried 
out on the top-ranked pose for each compound which meet the docking with 
pharmacophore constraints criteria. Due to the very high computation cost and 
time required to run each molecular dynamics simulation, only the top-ranked 
pose and the pose which fit alongside the JIP-binding pocket identified by the 
pharmacophore model were selected for molecular dynamics simulations. Poses 
which fit perpendicular across the JIP-binding pocket tend to show a less stable 
trajectory and were not selected for molecular dynamics simulations. A total of 9 
validation compounds and 9 ZINC database compounds were selected for 
molecular dynamics simulations.  
 
 A flowchart of steps taken in this phase of the research project is shown in 
















Table 3.3: Chemical structures of  validation compounds drawn using Marvin 



































-4.24 > 100 
3 
 
-3.64 > 100 
10 
 





Molecular dynamics simulations were carried out on compounds from the 
ZINC database. Three compounds (ZINC11681157, ZINC03405497 and 
ZINC09369056 were retained for further analysis of interaction profiles after 
having a docking score of -5 or less(Table 3.4). 
Table 3.4: Chemical structures and docking scores for molecular dynamics 






















 The population size of the top 3 clusters in each validation compound and 
three ZINC database compounds are listed in Table 3.5.  A representative pose 
from Cluster 1 is obtained for further analysis. 
Table 3.5: Cluster size and total population of each compound. Numbers in 
parenthesis refer to the percentage of population in their respective 




Cluster 1 Cluster 2 Cluster 3 Total 
population 
25 63 (63.0) 25 (25.0) 12 (12.0) 100 
19 75 (75.0) 11 (11.0) 8 (8.0) 100 
BI-98A10 55 (55.0) 26 (26.0) 17 (17.0) 100 
BI-90H8 47 (47.0) 31 (31.0) 9 (9.0) 100 
BI-90E2 60 (100.0) 0 (0.0) 0 (0.0) 60 
BI-90E7 13 (21.7) 13 (21.7) 8 (13.3) 60 
BI-83B3 11 (18.3) 10 (16.7) 7 (11.7) 60 
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3 80 (80.0) 11 (11.0) 9 (9.0) 100 
10 27 (45.0) 17 (28.3) 14 (23.3) 60 
ZINC11681157 170 (56.7) 118 (39.3) 12 (4.0) 300 
ZINC03405497 299 (99.7) 1 (0.3) 0 (0.0) 300 
ZINC09369056 209 (69.7) 73 (24.3) 6 (2.0) 300 
 
3.3.4 Analysis of interaction profiles 
 
 The hydrogen bond interactions between Thr 159 of JIP1 and Arg 127 of 
JNK1 were chosen to be included in the pharmacophore model and for further 
analysis of interactions. This is based on isothermal calorimetry experiments 
performed by Heo et al to measure dissociation constant (Kd) values of JIP1 to 
bind to wild-type JNK1 with Arg 127 and to mutant JNK1 with Ala 127 where 
the Kd values were 0.42 ± 0.13 μM and 6.4 ± 2.2 μM respectively[57]. 
 
Among each of the listed compounds, they show a relatively stable 
trajectory by maintaining their distance and interaction with Arg 127 throughout 
the entire simulation run.  
 
Analysis of the redocked and selected poses show that for the validation 
compounds, compounds 19(Figure 3.5) and 25 may potentially form pi-cationic 
interactions with Arg 127 through its thiophene carboxamide group and the 
distance between the geometric center of its thiophene group and Arg 127 is 
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maintained within 6 Å throughout most of the trajectory(Figures 3.6 and 3.7). 
Compound 19 potentially forms electrostatic interactions with Arg 127(Figure 
3.8), polar non-bonded contacts with Arg 127 and Ser 161(Figure 3.9) and 
hydrophobic non-bonded contacts with Ala 113, Val 118, Leu 123, Leu 131 and 
Val 159(Figure 3.10). Compounds BI-98A10 and BI-90H8 may potentially form 
pi-cationic interactions with Arg 127 through its thiadiazole group(Figures 3.11 to 
3.14). Both compounds may potentially form polar non-bonded contacts with Arg 
127(Figures 3.15 and 3.16), and form hydrophobic non-bonded contacts with Val 
118, Leu 123, Leu 131 and Val 159(Figures 3.17 and 3.18). For the decoy 
compounds BI-83B3, 3 and 10, when the distance between its aromatic thiophene 
group or 6-member ring is measured, the maximum distance is longer and the 
proportion of the trajectory where the distance is within 6 Å is smaller compared 









Figure 3.6: Graph of distance between geometric center of aromatic ring in 
Compound 19 and Arg 127 against instance in trajectory. A 6 







Figure 3.7: Graph of distance between geometric center of aromatic ring in 
Compound 25 and Arg 127 against instance in trajectory. A 6 




Figure 3.8: Pose of Compound 19 over ribbon diagram of JNK1. Charged 
residues within 4.0 Å distance are labelled. Potential electrostatic 
interactions within 4.0 Å distance from ligand with a preference 






Figure 3.9: Pose of Compound 19 over ribbon diagram of JNK1. Polar 
residues within 4.0 Å distance are labelled. Polar contact surfaces 





Figure 3.10: Pose of Compound 19 over ribbon diagram of JNK1. Hydrophobic 
residues within 4.0 Å distance are labelled. Hydrophobic contact 




















Figure 3.13: Graph of distance between geometric center of aromatic ring in 
Compound BI-98A10 and Arg 127 against instance in trajectory. A 




Figure 3.14: Graph of distance between geometric center of aromatic ring in 
Compound BI-90H8 and Arg 127 against instance in trajectory. A 






Figure 3.15: Pose of Compound BI-98A10 over ribbon diagram of JNK1. Polar 
residues within 4.0 Å distance are labelled. Polar contact surfaces 





Figure 3.16: Pose of Compound BI-90H8 over ribbon diagram of JNK1. Polar 
residues within 4.0 Å distance are labelled. Polar contact surfaces 







Figure 3.17: Pose of Compound BI-98A10 over ribbon diagram of JNK1. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Figure 3.18: Pose of Compound BI-90H8 over ribbon diagram of JNK1. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 






Figure 3.19: Graph of distance between geometric center of aromatic ring in 
Compound BI-83B3 and Arg 127 against instance in trajectory. A 





Figure 3.20: Graph of distance between geometric center of aromatic ring in 
Compound 3 and Arg 127 against instance in trajectory. A 6 






Figure 3.21: Graph of distance between geometric center of aromatic ring in 
Compound 10 and Arg 127 against instance in trajectory. A 6 
angstrom distance cutoff is shown as a dotted line. 
 
Table 3.6: Distance between geometric center of aromatic ring in compound 















19 4.5 0.67 3.6 7.7 96 
25 4.4 0.62 3.4 6.8 98 
BI-98A10 6.8 1.3 3.4 9.3 32 
BI-90H8 4.7 0.83 3.4 7.3 94 
BI-83B3 8.2 3.0 3.3 14 42 
3 5.6 1.9 3.5 12 54 
10 7.5 1.3 5.6 11 3.3 
 
BI-90H8 may potentially form hydrogen bond interactions with Arg 127 
through its thiazole group(Figures 3.22 and 3.23). The decoy compounds BI-90E2 
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and BI-90E7 have a longer maximum distance and the proportion of the trajectory 
where the distance is within 3.5 Å is smaller compared to BI-90H8(Figures 3.24 
and 3.25 and Table 3.7)[172]. 
 





Figure 3.23: Graph of distance between large atom in Compound BI-90H8 and 
Arg 127 against instance in trajectory. A 3.5 angstrom distance 






Figure 3.24: Graph of distance between large atom in Compound BI-90E2 and 
Arg 127 against instance in trajectory. A 3.5 angstrom distance 




Figure 3.25: Graph of distance between large atom in Compound BI-90E7 and 
Arg 127 against instance in trajectory. A 3.5 angstrom distance 
cutoff is shown as a dotted line. 
 
For the ZINC database compounds, they show ZINC09369056 changing 
conformation to point its thiazole sulfur towards the carbonyl after 1.6ns in the 
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simulation. This shows that the molecular dynamics is able to reduce the energy 
state of the ligand and gives valuable insights into the possible binding 
orientations of each ligand. ZINC03405497 is prioritized for in vitro testing after 
showing a very stable trajectory with its amide group remaining within hydrogen 
bond distance throughout the entire trajectory(Figure 3.26, Figure 3.27 and Table 
3.7). ZINC03405497 form potential electrostatic interactions and polar non-
bonded contacts with Arg 127 (Figure 3.28) and hydrophobic non-bonded 
contacts with Val 118, Leu 123, Leu 131, Val 159 and Trp 324(Figure 3.29).  
 






Figure 3.27: Graph of distance between large atom in ZINC03405497 and Arg 
127 against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 3.28: Pose of ZINC03405497 over ribbon diagram of JNK1. Charged 
residues within 4.0 Å distance are labelled. Potential electrostatic 
interactions within 4.0 Å distance from ligand with a preference 
for negatively charged atoms are shown as red spheres and 





Figure 3.29: Pose of ZINC03405497 over ribbon diagram of JNK1. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 
are shown as dotted green spheres. 
 

















within 3.5 Å 
BI-90H8 3.6 0.53 2.8 5.6 52 
BI-90E2 4.3 1.2 2.9 7.4 23 
BI-90E7 3.8 0.57 2.9 5.2 37 
ZINC11681157 5.5 0.83 3.7 8.0 0.0 
ZINC03405497 3.0 0.20 2.6 4.4 97 





 From the analysis of interactions in the molecular dynamics trajectories, 
the results are consistent with the reported small molecule inhibitors where 
thiazoles, thiadiazoles and thiophene carboxamides were investigated[82-84], as 
well as the QSAR study where JNK1-JIP1 inhibitors have hydrogen bond donor 
and acceptor properties and do not appear to form interactions through six-




In doing a virtual screening of ZINC database compounds to identify 
potent compounds that could potentially inhibit JNK1 at the JIP1 binding site, one 
ZINC database compound was identified that could be prioritized for in vitro 
testing. 
  
The entire virtual screening process is less accurate in ranking and 
filtering compounds among the validation compounds in the published JNK1-JIP1 
inhibitors dataset. These challenges remain difficult to address due to the large 
size of the JIP binding pocket where the exact location and binding pose for small 
molecule inhibitors are not known. Future work could include testing the 
identified compounds for biological activity and to refine the model by choosing a 
different part of the JIP1 binding site for docking, molecular dynamics 










 The compound BIRB796 (Doramapimod) has been found to bind to the 
DFG binding site of p38α and JNK2. Virtual screening of a subset of ZINC 
database compounds with a Tanimoto coefficient of up to 0.7 based on 
ChemAxon fingerprints[168] was carried out by docking and analysis of  
interaction profiles. A consensus model that analyzed docking scores using three 
docking software was used to filter and prioritize compounds for in vitro testing. 9 
ZINC database compounds and the positive control compound BIRB796 were 
selected for in vitro testing using the KINOMEScan test from DiscoveRx to 




4.2.1  Ranking of DFG inhibitors based on scoring function 
 
 The X-ray crystal structures of JNK2 with the DFG-in and DFG-out 
conformation were available in the RCSB Protein Databank website (PDB 
structures 3E7O and 3NPC respectively)[56,65,173]. The structures were 
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processed by adding hydrogen atoms, assigning tautomer and ionization states to 
the structure and capping terminal ends of the entire protein structure, removing 
water molecules in the structure and carrying out energy minimization of the 
structure using the Assisted Model Building with Energy Refinement 
99(AMBER99)[174] or Chemistry at HARvard Macromolecular Mechanics 
27(CHARMM27) forcefield[154,175]. 
 
A purchasable subset of compounds of up to 0.7 Diversity Index based on 
ChemAxon fingerprints that were compared to the compound within the most 
densely populated cluster in the ZINC chemical database[168,176] were 
downloaded and docking of the compounds was carried out on the DFG binding 
site of JNK2. 
 
The DFG binding site of JNK2 was defined by covering the following 
amino acid residues within the search space of the docking procedure. These 
amino acid residues consist of 12 hydrophobic residues (Ile 32, Val 40, Ala 53, 
Leu 76, Leu 77, Ile 86, Met 108, Leu 110, Met 111, Leu 142, Leu 168 and Phe 
170), 1 polar residue (Gln 37) and 6 polar and charged residues (Lys 55, Arg 69, 







4.2.2 Analysis of interaction profiles of identified DFG site inhibitors 
 
After refining the list of compounds based on the purchasable compounds 
criteria to enable convenient procurement of the compound from commercial 
vendors,  diversity index metric and the docking score in the structure-based 
study, the list of compounds were further refined for further analysis by 
identifying docked poses which fulfill at least one of the following criteria: 
 
1) The compound fits into the binding pocket that is defined to be the binding 
pocket that the compound BIRB796 occupies in the X-ray crystal structure 
of JNK2. 
2) The compound forms a H-bond interaction with Glu 73 or Asp 168 
 
MGLTools, Ligplot and Discovery Studio Visualizer were used to visually 
inspect the interactions that were formed. The binding poses and interaction map 
profiles were eventually used to select a list of promising compounds for purchase 
through commercial vendors and to determine Kd values of the compounds 
through in vitro testing on the KINOMEScan assay platform by DiscoveRx[177]. 
 
4.2.3 Preparation of compounds for in vitro testing 
 
 The solubility profiles of selected compounds were calculated using MOE 
2011.10 which calculates the LogS values based on the sum of all the atoms and 
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chemical bonds present in the molecule[178]. Compounds with LogS values 
above 4.0 or below -4.0 were not selected for purchase. The chemical structures 
and Chemical Accession Service (CAS) numbers of selected compounds were 
used to obtain permission from the relevant authority to import into the 
country[169]. The compounds were prepared in 100 µL of dimethyl sulfoxide 
(DMSO) solution at 10mM concentration under collaboration with Life Sciences 
Institute and Laboratory of Liver Cancer and Drug-induced Liver Diseases 
Research at National University of Singapore. 
 
4.3 Results and discussion 
 
4.3.1 Consensus scoring functions using different docking software 
 
The docking score and Tanimoto coefficients for each compound 
compared to the positive validation compound BIRB796 are listed in Table 4.1. 
Compounds with a higher docking score in SYBYL and compounds with a more 
negative docking score in MOE or AutoDock Vina indicate a higher chance of 












Table 4.1: Results of docking scores on various ZINC compounds using 
different docking software. 
 















16 -9.6 -14 - - 
ZINC00088624 
 
4.6 -6.8 -7.7 -6.3 0.25 
ZINC00210429 
 
5.1 -6.0 -7.1 -8.2 0.25 
ZINC00344359  
 
5.5 -6.0 -6.9 -8.4 0.16 
ZINC02026664  
 





7.1 -6.4 -7.5 -7.9 0.11 
ZINC05019440 
 




2.6 -6.1 -6.5 -7.3 0.09 
ZINC06692943  
 
6.4 -6.4 -7.7 -7.4 0.08 
ZINC13118854  
 
7.3 -6.9 -7.8 -8.8 0.16 
ZINC31166436  
 
8.3 -7.7 -6.8 -7.6 0.06 
ZINC05417635 
 
7.0 -7.1 -8.3 -9.4 0.12 
ZINC01718148 
 





6.4 -6.3 -7.9 -7.5 0.12 
ZINC03178796  
 
7.4 -7.4 -7.1 -9.2 0.22 
ZINC08659433 
 
5.1 -6.7 -8.0 -9.8 0.13 
ZINC05799999 
 
7.1 -7.1 -8.0 -8.9 0.12 
ZINC39955766 
 
5.6 -6.5 -7.2 -9.8 0.3 
 
4.3.2 KINOMEScan assay 
 
 The KINOMEScan assay platform by DiscoveRx was used to determine 
the Kd values of selected ZINC database compounds on JNK1, JNK2 and p38α. 
The positive validation control BIRB796 showed significant binding and Kd 
values at nanomolar concentrations on JNK2 and p38α, while all the ZINC 
database compounds did not show any significant binding at concentrations of up 
to 40μM. The percentage inhibition profile for ZINC13118854 was inconclusive 
as one experimental arm showed no change in signal strength and the second 
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experimental arm showed near full reduction in signal strength at 40 μM 
concentration (Table 4.2). 
 
Table 4.2: KINOMEScan assay results. 
Name of 
compound 
JNK1 JNK2 p38α 
BIRB796 / 
Doramapimod 
Kd = 15 μM Kd = 1.8 nM Kd = 4.7 nM 
ZINC00088624 Kd > 40 μM 
% inhibition = 2 % 
Kd > 40 μM 
% inhibition = 19 % 
Kd > 40 μM 
% inhibition = 1 % 
ZINC13118854 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 7 % 
Kd > 40 μM 
Inconclusive 
ZINC05019440 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 3 % 
ZINC06692943 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 3 % 
Kd > 40 μM 
% inhibition = 10% 
ZINC04266305 Kd > 40 μM 
% inhibition = 20 % 
Kd > 40 μM 
% inhibition = 8 % 
Kd > 40 μM 
% inhibition = 9 % 
ZINC02026664 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 12 % 
Kd > 40 μM 
% inhibition = 3 % 
ZINC00210429 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 2 % 
Kd > 40 μM 
% inhibition = 1 % 
ZINC00344359 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 2 % 
Kd > 40 μM 
No inhibition 
ZINC06320732 Kd > 40 μM 
No inhibition 
Kd > 40 μM 
% inhibition = 2 % 
Kd > 40 μM 




 This shows that random docking even with consensus scoring and analysis 
of interaction fingerprint profile is insufficient to accurately rank and classify 
compounds with a very high chance for false positives and a very low hit rate. 
Further work that includes docking with pharmacophore constraints and 





 In doing a virtual screening of ZINC database compounds to identify 
potent compounds that could potentially inhibit JNK2 at the DFG binding site, 9 
compounds were found to show no significant binding using the KINOMEScan 
assay platform. Future work could include testing a larger number of identified 


















 The compound rifampicin has been found to bind to human PXR and an 
X-ray crystal structure of rifampicin in human PXR is available in the Protein 
Databank. A structure-based study was carried out where rifampicin, 5 non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and 1 chemical compound 
pregnenolone carbonitrile were docked in the ligand-binding domain of human 
PXR with molecular dynamics simulations and docking to filter and select poses 
for further study. 
 
5.2 Structures of human PXR 
 
The structures of human PXR consist of a ligand-binding domain, a co-
activator domain and a complex binding interface between PXR and RXR. The 
ligand-binding domain was chosen as the initial site for study in this project as 
there are 9 X-ray crystal structures that are available in the Protein Databank 
database[75,86,109-113], as well as several site-directed mutagenesis studies in 
the literature which help to elucidate the location and mechanism of binding for 
various strong activators within the ligand-binding domain[85,86,112]. 
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Attempting a docking study and molecular dynamics study of various ligands in 
this pocket has several challenges. Due to the very large and highly flexible nature 
of this binding pocket[75,111,112,114], this binding domain has a very high 
capacity to change conformation and accept a wide variety of ligands, with a 
reported ligand promiscuity index of 1.006 for human PXR by using molecular 
quantum number (MQN) distances and ChEMBL activity datasets[23,179]. In 
addition, there is also currently a large knowledge gap in this area where the 
mechanism of binding and the X-ray crystal structure or NMR structure of PXR is 
not known with regard to partial agonists and antagonists that bind to this pocket. 
Hence, the study of agonists or activators of PXR will be carried out in this 
project. 
 
 The interactions that may play a role in activating human PXR occur at the 
following residues: Ser-247, Gln-285, Phe-288, Trp-299, Tyr-306, His-407 and 
Arg-410 as mutagenesis studies have shown changes in human PXR activity on 
hyperforin[112], SR12813, rifampicin[86] or bisphenol A[85].  
 
 The human PXR ligand binding domain consist of 15 hydrophobic 
residues (Val-211, Leu-240, Met-243, Phe-251, Phe-281, Phe-288, Trp-299, Leu-
308, Met-323, Leu-324, Leu-411, Ile-414, Phe-420, Met-425, and Phe-429), four 
polar residues (Ser-247, Cys-284, Gln-285, and Tyr-306), and four charged 




 The co-activator domain functions by accepting co-activators in PXR and 
RXR and increasing the length, duration and stability of binding and activation by 
ligands, as well as by decreasing the possible number of poses that the ligands 
might adopt on binding at the ligand-binding site[111]. Due to the difficulty in 
designing and studying protein-protein docking and interactions, the study of 
possible compounds for co-activators will not be carried out in this project. 
 
5.3 Materials and methods 
 
5.3.1 Biological activity 
  
Biological activity data was obtained from collaboration with Faculty of 
Pharmaceutical Sciences in University of British Columbia at Vancouver. 
Firefly/Renilla luciferase assay was used to obtain CYP3A4 gene expression and 
PXR activation. Rifampicin was used as the positive control, pregnenolone 
carbonitrile (PCN) was used as the negative control, dimethyl sulfoxide (DMSO) 
was used as the vehicle control, and five non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) delavirdine, etravirine, rilpivirine, nevirapine and efavirenz 







5.3.2  Initial docking of compounds 
 
  The X-ray crystal structure of human PXR as a monomer with rifampicin 
as the co-crystal structure (PDB structure: 1SKX) was used in this docking study. 
The structures were processed by adding hydrogen atoms, assigning protons and 
partial charges to the structure and capping terminal ends of the entire protein 
structure[152], removing water molecules in the structure and carrying out energy 
minimization of the structure using the Assisted Model Building with Energy 
Refinement 99(AMBER99)[174] or Chemistry at HARvard Macromolecular 
Mechanics 27 (CHARMM27) forcefield[154,175]. The docking function in MOE 
was used to dock each molecule to human PXR.  The induced-fit docking setting 
was used, due to the highly flexible region of the ligand binding 
site[75,111,112,114].  This setting uses a London dG scoring function, a force 
field refinement scheme to refine the docked molecules and to tether the positions 
of the side chains of the 23 residues surrounding the active site to allow a certain 
degree of movement of each side chain.  The molecular mechanics generalized 
Born/volume integral (MM/GBVI) binding free energy is calculated as a final 
pose rescoring function to refine the docking pose.  One hundred possible poses 
were determined for each molecule[156-158]. 
 
The top-ranked pose with the best MM/GBVI binding free energy was 
selected for analysis of interaction with human PXR if it fulfilled at least one of 




1) the compound fits into the Trp-299 site;  
2)  a H-bond acceptor of the compound interacts with either the His-407 or 
Gln-285 side chain;  
3)  the compound forms an interaction with Ser-247, Phe-288 or Trp-299. 
 
5.3.3 Analysis of interactions 
 
 A similar workflow to Figure 3.4 was carried out where molecular 
dynamics simulations were carried out on the top-ranked docked pose from the 
initial docking study. Compounds which show an unstable trajectory or had a 
docking score that did not meet a cut-off criteria were not included in the 
redocking experiments.  Redocking experiments using MOE 2013.10 were carried 
out for the structure of rifampicin from the PubChem database and for filtered 
compounds. Poses which have hydrogen bond or pi interactions that are consistent 
with molecular dynamics simulations are selected for further analysis of potential 









5.4 Results and discussion 
 
5.4.1 Initial docking results 
 
To validate the docking process, the structure of rifampicin taken from 
PDB database was redocked into the same ligand binding domain and the best 
binding pose was copied and superimposed over the original binding position in 
PDB structure 1SKX and had a RMSD of 1.02 Å.  This shows that the docking 
process was able to dock rifampicin as a positive control accurately onto the 
ligand-binding domain. 
 
Table 5.1 shows the MM/GBVI binding free energy for the top-ranked 
pose of each compound and the various controls. Compared wiith rifampicin 
(positive control), the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
had weaker binding free energy.  Among the five individual NNRTIs, the rank 
order was delavirdine > etravirine > rilpivirine > nevirapine > efavirenz. This 
shows that the docking process is able to rank the positive compounds rifampicin, 
etravirine and rilpivirine accurately. The docking process is also able to rank the 
negative compounds nevirapine and PCN accurately. Delavirdine was ranked as a 
false positive, and efavirenz was ranked as a false negative. 
 
The correlation curves for MM/GBVI binding free energy or molecular 
weight against observed experimental values are shown in Figures 5.1 and 5.2 
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with a squared correlation coefficient of 0.44 and 0.51 respectively. This shows 
that there is a certain trend and a higher chance to predict higher fold increase in 
human PXR activity with increasing molecular weight and more negative 
MM/GBVI binding free energy values. This could be due to the increased number 
of pharmacophoric features that would be present in larger molecule compounds 
and the inherent capacity for PXR to adopt large changes in conformation within 
its ligand-binding domain and hence having a very high ligand promiscuity index.  
 







Human PXR Activity 
(Fold increase in 
Firefly/Renilla 







Rifampicin 822.94 20 -13.1 
Delavirdine 456.56 2.0 -9.1 
Etravirine 435.28 17 -7.9 
Rilpivirine 366.42 11.5 -7.9 




341.49 1.5 -6.5 





Figure 5.1: Correlation curve for MM/GBVI binding free energy (y-axis) 





Figure 5.2: Correlation curve for molecular weight (y-axis) against fold 
increase in human PXR activity over vehicle control (x-axis). 
 
 
5.4.2 Analysis of interactions 
 
Table 5.2 lists the amino acid residues that are in contact and may form 
interactions with the selected ligand pose. The molecular dynamics and redocking 




Table 5.2: Amino acid residues involved in the binding of compounds to 
human PXR 
  
Compound Hydrophobic residues Polar 
residues 
Figures 
Etravirine Leu 240, Met 243, Phe 281, Phe 288, 
Met 323, Leu 411, Phe 420, Met 425, 
Phe 429 
Gln 285 5.3, 5.5 
Rilpivirine Val 211, Met 243, Phe 288, Trp 299, 
Met 323, Leu 324, Leu 411, Ile 414, 
Phe 420, Met 425, Phe 429 
Gln 285 5.6, 5.8 




 The X-ray structure of rifampicin in human PXR show potential hydrogen 
bond interactions that may take place between the ester group in rifampicin and 
Ser 247 in human PXR(Table 5.3). The redocking process is less successful in 
docking the larger structure of rifampicin taken from PubChem database where all 










Potential hydrogen bond interactions take place between the nitrile group 
in etravirine and Gln 285(Figures 5.3, 5.4 and Table 5.3).  
 




Figure 5.4: Graph of distance between large atom in etravirine and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 5.5 Pose of etravirine over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Potential hydrogen bond interactions take place between the nitrile group 









Figure 5.7: Graph of distance between large atom in rilpivirine and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 





Figure 5.8: Pose of rilpivirine over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Potential hydrogen bond interactions take place between the amide group 
in efavirenz and His 407 in human PXR(Figures 5.9, 5.10 and Table 5.3). 
 





Figure 5.10: Graph of distance between large atom in efavirenz and His 407 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 5.11: Pose of efavirenz over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 








 No consistent set of hydrogen bond interactions or pi-interactions are 
found among poses obtained through clustering in molecular dynamics 
simulations. The distance between the amide group in delavirdine and His 407 is 
shown in Figure 5.12 and Table 5.3. 
 
Figure 5.12: Graph of distance between large atom in efavirenz and His 407 
against instance in trajectory. A 3.5 angstrom distance cutoff is 
shown as a dotted line. 
 
Pregnenolone carbonitrile (PCN) 
  
No consistent hydrogen bond interactions of within 3.5 Å in length or 
aromatic pi interactions are found among the representative poses. The distance 





Figure 5.13: Graph of distance between large atom in PCN and His 407 against 





 No consistent hydrogen bond interactions of within 3.5 Å in length or 
aromatic pi interactions are found among the representative poses. The distance 
between the amide group in nevirapine and His 407 is shown in Figure 5.14 and 
Table 5.3. 
 
Figure 5.14: Graph of distance between large atom in nevirapine and His 407 
against instance in trajectory. A 3.5 angstrom distance cutoff is 
shown as a dotted line. 
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Table 5.3: Distance between first set of compounds and residue where 






















Rifampicin O – Ser 
247 
4.6 0.76 2.7 8.1 11 
Etravirine N – Gln 
285 
5.1 1.4 2.9 11.3 8.0 
Rilpivirine N – Gln 
285 
4.1 0.89 2.9 7.9 16 
Efavirenz  O – His 
407 
3.9 1.1 2.7 10 22 
Delavirdine O – His 
407 
10 1.8 4.3 14 0 
Pregnenolone 
carbonitrile 
N – His 
407 
5.3 0.81 3.5 8.6 0 
Nevirapine O – His 
407 




 A structure-based study was carried out on 5 NNRTIs, one antibiotic and 
one chemical compound on the X-ray crystal structure of human PXR. The 
workflow was able to filter and rank human PXR activators based on a set of 
possible binding orientations and docked scores.  Additional future work will 
refine the model by applying a similar method on a larger set of compounds on 











 A homology model of zebrafish PXR was created using templates of 
human PXR from the Protein Databank and the primary structure of zebrafish 
PXR in the UniProt database. A structure-based study was carried out where 10 
approved drugs were docked in the ligand-binding domain of human and 
zebrafish PXR. Molecular dynamics simulations were carried out on the docked 
poses and a separate set of docking experiments were carried out to select poses 
for further analysis of binding surfaces and binding orientations. 
 
6.2 Introduction to zebrafish PXR 
 
 While attempts have been made to develop in vitro assays to profile 
efficiently the effects of new compounds on CYP3A4 expression levels, these 
efforts are made difficult by species-specific effects that have limited the use of 
animal tissues and cells for testing purposes. Since analysis of the effects of 
compounds on CYP3A4 gene expression has been largely restricted to laborious 
assays involving human liver tissue, an alternative in vivo study was carried out 
by Metabolic Profile Research Group in which zebrafish Danio rerio was used to 
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investigate the effects of various approved drugs on CYP3A4 gene expression and 
PXR activation in zebrafish due to the easier accessibility, lower cost and shorter 
waiting period in obtaining zebrafish for testing of biological activity[122,124-
126]. Although human microsomes are available commercially, a zebrafish 
animal model is sufficiently small to be used in small assay well plates for high-
throughput screening. 
 
 Induction of zebrafish CYP3A4 gene expression is similar to human 
CYP3A4 gene expression for most of the tested approved drugs where most of the 
compounds are able to induce an increase in CYP3A4 gene expression[126,182]. 
Two of the tested compounds rifampicin and pioglitazone show differences in 
biological activity between human and zebrafish and acetaminophen does not 
appear to induce increased expression of CYP3A4 in both human and zebrafish. 
Hence, acetaminophen will be used as the negative control compound in this 
study. 
 
6.3 Materials and methods 
 
6.3.1 Biological activity 
 
 Biological activity data was obtained from published studies[182] and 
from collaboration with Metabolic Profiling Research Group in Department of 
Pharmacy, National University of Singapore. CYP3A4 gene expression data was 
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obtained using the P450-GloTM CYP3A4 assay kit.  Rifampicin and 
dexamethasone were used as the positive controls, acetaminophen was used as the 
negative control in this study, and seven approved drugs phenytoin, 
carbamazepine, nafcillin, efavirenz, pioglitazone, prednisone and rufinamide were 
tested for biological activity[126]. 
 
6.3.2 Homology modeling of zebrafish PXR 
 
 There are nine X-ray crystallography structures of human pregnane X 
receptor (PXR)-ligand complexes in the RCSB Protein Data Bank[75,86,109-
113].  As rifampicin was chosen as the positive validation compound for this 
study, the structure (PDB ID: 1SKX) was chosen as that structure has rifampicin 
as the co-crystallized ligand[86].  For zebrafish PXR, only the primary structure is 
available in the UniProt database[183]. Therefore, a homology model of zebrafish 
PXR is created using the PDB structure 1SKX as a template. 
 
Molecular Operating Environment (MOE) 2011.10[153]  was used for 
creating the homology model of zebrafish PXR and for docking the individual 
compounds to the 1SKX structure. 1SKX was first processed by removing bound 
ligand and water molecules.  Hydrogen atoms were then added, and ionization 
states were assigned using the Protonate3D function in MOE[152].  The Assisted 
Model Building with Energy Refinement 99 (AMBER99) forcefield was used to 
create the homology model, and to carry out energy minimization of the 
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homology model and the structure 1SKX[154].  The target sequence has an 
identity value of 41.4%. The Maestro software in Schrödinger 2015-3[184] is 
used to carry out comparison of amino acid sequence between the homology 
model of zebrafish PXR and human PXR(Figure 6.1) and to carry out 
Ramachandran plot of the PDB structures 1SKX(Figure 6.2) and the created 
zebrafish homology model(Figure 6.3). All non-glycine and non-binding site 
residues which do not fulfill the dihedral angle criteria[185] are removed from the 
model where in the zebrafish homology model, the removed residues are Ile 195, 
Lys 228, His 359 and Ser 433. 
 
Figure 6.1: Amino acid sequence for homology model of zebrafish PXR and 
human PXR using PDB structure 1SKX as template. Conserved 
residues are highlighted in green and important residues that are 









Figure 6.3: Ramachandran plot of homology model of zebrafish PXR.  
6.3.3 Structure-based study of compounds 
 
  An initial docking process similar to section 5.3.2 was carried out in this 
phase of the research project as it was able to accurately dock the positive 
validation compound rifampicin within 2.0 Å of its X-ray structure and also rank 
the compound accurately as a strong human PXR activator. The molecular 
mechanics generalized born/volume integral (MM/GBVI) binding free energy is 
calculated as a final pose rescoring function to refine the docking pose. Five 




The individual atom coordinates of each ligand’s possible docked pose 
were then recorded and hierarchical clustering using the Ward method[186,187] 
was carried out on each ligand to determine the most likely poses that were 
predicted to occur.  The representative pose from the most populated cluster was 
selected for further analysis. 
  
The pose was superimposed on the binding pocket of zebrafish PXR to 
compare their structural interaction fingerprint. Energy minimization was carried 
out to refine the docked pose if there is a clash with any residue in the binding 
pocket. JMP Version 10[188]  was used to perform the hierarchical clustering to 
choose representative poses from the most populated cluster for each docked 
compound. 
 
Molecular dynamics simulation, docking and analysis of binding site 
surface was carried out similar to the workflow in Figure 3.4. 
 
6.4 Results and Discussion 
 
6.4.1 Structures of human and zebrafish PXR 
 
Table 6.1 below lists the amino acid residues which surround the ligand-
binding domain of human and zebrafish PXR. 
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Table 6.1: List of amino acid residues that form the ligand-binding domain in 
human PXR and zebrafish PXR.  Important residues that are 
reported to activate human PXR are highlighted in bold. 
 
Residue in human PXR Corresponding Residue in zebrafish PXR 
Val 211 Thr 
Leu 240 Leu 
Met 243 Phe 
Ser 247 Thr 
Phe 251 Ile 
Phe 281 Phe 
Cys 284 Ile 
Gln 285 Leu 
Phe 288 Phe 
Trp 299 Trp 
Tyr 306 Tyr 
Leu 308 Met 
Glu 321 Asp 
Met 323 Met 
Leu 324 Met 
His 327 His 
His 407 Tyr 
Arg 410 Gln 
Leu 411 Val 
Ile 414 Ile 
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Phe 420 Glu 
Met 425 Trp 
Phe 429 Ile 
 
6.4.2 Initial docking results 
 
 Due to the large number of poses that were predicted by docking for each 
compound, an analysis of the interaction profile was carried out based on the top-
scoring docked pose, as well as through carrying out hierarchical clustering using 
the Ward method[186,187] to filter and refine the number of docked poses for 
further analysis. To validate the docking and hierarchical clustering process, the 
structure of rifampicin obtained from PDB database was redocked into the same 
ligand binding domain and the top-scoring pose and the binding pose from the 
most populated cluster had a root mean squared distance (RMSD) of 1.0 Å with 
the original binding position in PDB structure 1SKX.  This shows that the 
docking process was able to dock rifampicin as a positive control accurately onto 
the ligand-binding domain. Table 6.2 lists the docked score of the representative 







































































 The docking and clustering process was able to rank and classify most of 
the compounds as possible activators. However, it ranked certain weak or non-
activators as strong activators and vice versa. Additional further study through 
molecular dynamics simulations and analysis of structural interactions would be 
required. 
 
6.4.3 Analysis of interactions 
 
Table 6.2 lists the amino acid residues that are in contact and may form 
interactions with the selected ligand pose. The molecular dynamics and redocking 
results are presented for each compound in this section. 
 
Table 6.3: Amino acid residues involved in the binding of compounds to 
human PXR. 
  
Compound Hydrophobic residues Polar 
residues 
Figures 
Phenytoin Val 211, Met 243, Phe 281, Phe 288, 
Trp 299, Met 323 
Gln 285 6.6, 6.8 
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Carbamazepine Met 243, Phe 281, Phe 288, Trp 299, 
Met 323, Leu 411, Met 425, Phe 429 
Ser 247 6.12, 6.14 
Dexamethasone Val 211, Leu 240, Met 243, Phe 
251, Phe 281, Phe 288, Trp 299, Met 
323, Leu 411 
Gln 285 6.18 , 6.20 
Nafcillin Val 211, Leu 240, Met 243, Trp 299, 
Leu 308,  Met 323, Leu 324, Leu 
411, Ile 414, Phe 420 
Gln 285 6.24, 6.26 
Prednisone Val 211, Leu 240, Met 243, Phe 
281, Trp 299, Met 323, Leu 324, 
Leu 411, Ile 414 
Gln 285 6.37, 6.39 
 
Table 6.4: Amino acid residues involved in the binding of compounds to 
zebrafish PXR. 
 
Compound Hydrophobic residues Figures 
Phenytoin Phe 243, Phe 288, Trp 299 6.9, 6.11 
Carbamazepine Thr 211, Phe 243, Phe 288, Trp 299, 
Met 323, Met 324 
6.15, 6.17 
Dexamethasone Thr 211, Leu 240, Phe 243, Phe 281, 
Phe 288 
6.21, 6.23 
Nafcillin Thr 211, Let 240, Phe 243, Met 323, 
Met 324 
6.27, 6.29 
Efavirenz Thr 211, Leu 240, Phe 243, Met 




Pioglitazone Thr 211, Leu 240, Phe 243, Thr 247, 
Trp 299, Val 411, Ile 414, Trp 425 
6.33, 6.35 
Prednisone Thr 211, Leu 240, Phe 243, Trp 299, 






The X-ray structure of rifampicin in human PXR show potential hydrogen 
bond interactions that may take place between the ester group in rifampicin and 
Ser 247 in human PXR(Table 5.3). Molecular dynamics simulations show 
rifampicin in human PXR have a larger percentage of instances within hydrogen 
bond distance to Ser 247 in the trajectory(Figure 6.4) compared to rifampicin in 
zebrafish PXR with the equivalent residue Thr 247(Figure 6.5). The redocking 
process is less successful in docking the larger structure of rifampicin taken from 
PubChem database in both human and zebrafish PXR. In human PXR, poses 
which meet a cut-off filter of having a docking score of -5 or less are obtained, 
however all the poses have a RMSD of greater than 2.0 Å. In zebrafish PXR, all 




Figure 6.4: Graph of distance between large atom in rifampicin and Ser 247 
against instance in trajectory. A 3.5 angstrom distance cutoff is 
shown as a dotted line. 
 
 
Figure 6.5: Graph of distance between large atom in rifampicin and Thr 247 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Potential hydrogen bond interactions occur between the amide group in 
phenytoin and Gln 285 in human PXR(Figures 6.6 and 6.7) . In zebrafish PXR, 
potential pi interactions occur between the aromatic rings in phenytoin and the 
117 
 
conserved residue Phe 288(Figures 6.9 and 6.10) . Hence, phenytoin was 
predicted to activate both human and zebrafish PXR.  
 
Figure 6.6: Pose of phenytoin in human PXR. Potential interactions are 




Figure 6.7: Graph of distance between large atom in phenytoin and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.8: Pose of phenytoin over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 










Figure 6.10: Graph of distance between geometric center of aromatic ring in 
phenytoin and Phe 288 against instance in trajectory. A 4.0 




Figure 6.11: Pose of phenytoin over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 









Potential hydrogen bond interactions occur between the amide group in 
carbamazepine and Ser 247 in human PXR(Figures 6.12 and 6.13) . In zebrafish 
PXR, potential pi interactions occur between the aromatic rings in carbamazepine 
and the conserved residue Phe 288(Figures 6.15 and 6.16). Hence, carbamazepine 
was predicted to activate both human and zebrafish PXR. 
 
Figure 6.12: Pose of carbamazepine in human PXR. Potential interactions are 





Figure 6.13: Graph of distance between large atom in carbamazepine and Ser 
247 against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.14: Pose of carbamazepine over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 










Figure 6.16: Graph of distance between large atom in carbamazepine and Phe 
288 against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.17: Pose of carbamazepine over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




 Potential hydrogen bonds occur between the hydroxyl groups in 
dexamethasone and Gln 285 in human PXR(Figures 6.18 and 6.19). In zebrafish 
PXR, potential hydrogen bonds occur between the hydroxyl groups in 




Figure 6.18: Pose of dexamethasone in human PXR. Potential interactions are 




Figure 6.19: Graph of distance between large atom in dexamethasone and Gln 
285 against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.20: Pose of dexamethasone over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Figure 6.21: Pose of dexamethasone in zebrafish PXR. Potential interactions are 





Figure 6.22: Graph of distance between large atom in dexamethasone and Met 
323 against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.23: Pose of dexamethasone over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 








 Potential hydrogen bonds occur between the amide group in nafcillin and 
Gln 285 in human PXR(Figures 6.24 and 6.25). In zebrafish, potential hydrogen 
bonds occur between the amide group and Met 323(Figures 6.27 and 6.28). 
 
Figure 6.24: Pose of nafcillin in human PXR. Potential interactions are marked 





Figure 6.25: Graph of distance between large atom in nafcillin and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.26: Pose of nafcillin over ribbon diagram of human PXR. Hydrophobic 
residues within 4.0 Å distance are labelled. Hydrophobic contact 







Figure 6.27: Pose of nafcillin in zebrafish PXR. Potential interactions are 




Figure 6.28: Graph of distance between large atom in nafcillin and Met 323 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.29: Pose of nafcillin over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 





 In zebrafish PXR, potential hydrogen bonds occur between the amide 




Figure 6.30: Pose of efavirenz in zebrafish PXR. Potential interactions are 




Figure 6.31: Graph of distance between large atom in efavirenz and Met 323 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.32: Pose of efavirenz over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Potential pi interactions occur between the thiazolidinedione group in 
pioglitazone and the conserved residue Trp 299 in zebrafish PXR(Figures 6.33 
and 6.34). In human PXR, this distance is longer during molecular dynamics 
simulations(Figure 6.36). Hence, pioglitazone is predicted to activate zebrafish 





Figure 6.33: Pose of pioglitazone in zebrafish PXR. 
 
Figure 6.34: Graph of distance between geometric center of aromatic ring in 
pioglitazone and Trp 299 in zebrafish PXR against instance in 






Figure 6.35: Pose of pioglitazone over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




Figure 6.36: Graph of distance between geometric center of aromatic ring in 
pioglitazone and Trp 299 in human PXR against instance in 







Potential hydrogen bonds occur between the carbonyl group in prednisone 
and Gln 285 in human PXR(Figures 6.37 and 6.38). In zebrafish PXR, potential 
hydrogen bonds occur between the hydroxyl group in prednisone and the 
conserved residue Met 323(Figures 6.40 and 6.41).   
 
Figure 6.37: Pose of prednisone in human PXR. Potential interactions are 






Figure 6.38: Graph of distance between large atom in prednisone and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.39: Pose of prednisone over ribbon diagram of human PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 






Figure 6.40: Pose of prednisone in zebrafish PXR. Potential interactions are 




Figure 6.41: Graph of distance between large atom in prednisone and Met 323 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.42: Pose of prednisone over ribbon diagram of zebrafish PXR. 
Hydrophobic residues within 4.0 Å distance are labelled. 
Hydrophobic contact surfaces within 4.0 Å distance from ligand 




No consistent set of hydrogen bond or pi interactions are observed in 




Figure 6.43: Graph of distance between large atom in rufinamide and Ser 247 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.44: Graph of distance between large atom in rufinamide and Gln 285 
against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.45: Graph of distance between large atom in rufinamide and His 407 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.46: Graph of distance between geometric center of aromatic ring in 
rufinamide and Phe 288 in human PXR against instance in 






Figure 6.47: Graph of distance between large atom in rufinamide and Met 323 
against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.48: Graph of distance between geometric center of aromatic ring in 
rufinamide and Phe 288 in zebrafish PXR against instance in 






Figure 6.49: Graph of distance between geometric center of aromatic ring in 
rufinamide and Trp 299 in zebrafish PXR against instance in 




No consistent set of hydrogen bond or pi interactions are observed in 
human PXR(Figures 6.50 to 6.53) and in zebrafish PXR(Figures 6.54 and 6.55). 
 
Figure 6.50: Graph of distance between large atom in acetaminophen and Ser 
247 against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.51: Graph of distance between large atom in acetaminophen and Gln 
285 against instance in trajectory. A 3.5 angstrom distance cutoff is 




Figure 6.52: Graph of distance between large atom in acetaminophen and His 
407 against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.53: Graph of distance between geometric center of aromatic ring in 
acetaminophen and Phe 288 in human PXR against instance in 




Figure 6.54: Graph of distance between large atom in acetaminophen and Met 
323 against instance in trajectory. A 3.5 angstrom distance cutoff is 






Figure 6.55: Graph of distance between geometric center of aromatic ring in 
acetaminophen and Phe 288 in zebrafish PXR against instance in 
trajectory. A 4.0 angstrom distance cutoff is shown as a dotted line. 
 
Table 6.5: Distance between second set of compounds and residue where 
































































































































5.8 1.9 3.3 12 1.6 
 
Table 6.6: Distance between geometric center of aromatic rings in second set 































5.0 1.2 3.4 8.7 17 
Pioglitazone 
(Human PXR) 




3.8 0.33 3.3 5.9 72 
Rufinamide 
(Human PXR) 




5.9 2.5 3.4 12 5.0 
Acetaminophen 
(Human PXR) 




5.4 0.96 3.7 9.2 0.91 
 
 
6.4.4 Molecular dynamics as a filter tool 
 
 An initial docking with pharmacophore constraints was carried out. This 
process was able to filter out poses for molecular dynamics simulations, however 
this method to filter and select poses was less accurate in showing a pose that is 
consistent with molecular dynamics simulations. The selected poses were also 
less likely to show a stable ligand conformer. Hence, molecular dynamics was 
carried out and clustering of each trajectory was carried out to select 
representative poses for further analysis. Initially, attempts were made to correlate 
biological activity with molecular dynamics trajectory data by measuring ligand 
RMSD, all-atoms RMSD, distance between large atoms and distance between 
geometric center of aromatic rings.  Obtaining the distance between large atoms 
where hydrogen bonds could potentially form and distance between geometric 
148 
 
center of aromatic rings where pi interactions could potentially form was able to 
obtain a more accurate correlation with the obtained biological activity in human 
and zebrafish PXR. The selection of poses through clustering of a molecular 
dynamics trajectory was less accurate in obtaining stable low-energy conformers 
of the ligand. Attempts were made to redock the ligand on the same binding 
pocket, select poses that are consistent with the molecular dynamics trajectory 
data and fulfill a docking score cut-off criteria between reported PXR activators 
and non-activators and energy minimization of the ligand using a forcefield 
parameterized for small organic molecules was carried out to select and obtain the 
best lowest energy conformers for further analysis of electrostatic, polar and 
hydrophobic surfaces surrounding the ligand. This method of combining 
molecular dynamics simulations with earlier docking methods that include 
pharmacophore modelling, as well as docking for pose prediction with ligand 
energy minimization and analysis of binding site surfaces appear to provide more 
insight on the interactions between the ligand and binding site, and could 
potentially be used as a starting point for future work in studying PXR activity 











 From available X-ray crystal structures of human PXR, a homology model 
of zebrafish PXR was developed using the human PXR crystal structure as a 
template. 
 
 A workflow that is similar to the workflow being carried out in chapter 3 
appears to show promising results that could be used as starting points to study 
further human and zebrafish PXR activity as well as to improve on the prediction 
of CYP3A4 activity using computational models. The data are consistent with 
available X-ray structures and site-directed mutagenesis studies on human PXR in 
the literature where three non-conserved polar residues(Ser 247, Gln 285 and His 
407) and three conserved hydrophobic residues(Phe 288, Trp 299 and Met 323) 
could have an effect on human and zebrafish PXR activation and could be used to 
screen other compounds to rank and predict PXR activity. 
 
 Conformational energies and hydrogen bond geometries were not taken 
into account in this research project. This could be a potential future area to 











7.1 Major findings 
 
7.1.1 Ligand-based study 
 
 The QSAR model being developed had a consensus model of 2 Naïve 
Bayes and 3 support vector machine (SVM) modelling methods as these 
modelling methods are less sensitive and hence have a lower capacity for the 
model to be biased due to differences in distance between each object or 
datapoint. 
 
 The model being developed was also able to determine that 1D and 2D 
descriptors were sufficient to build a model that was able to predict the 
compounds in the validation sets well without including additional 3D 
descriptors. 
 
 With the additional criteria of including multiple thresholds to define the 
applicability domain of the model, and to perform a more rigorous 5-fold external 
cross-validation of the model by splitting the dataset into 5 equal parts and using a 
different dataset each time to train the model and test on the validation set, the 
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additional methods were able to predict each compound in the validation set, 
testing set and ZINC chemical library with a certain degree of confidence, and the 
additional results of using a different consensus model to screen through 5 
different validation sets enable a more representative view and analysis of the 
results of the ligand-based study. 
 
 Among the purchasable ZINC database compounds that were screened in 
the ligand-based study, 45673 compounds were identified for further analysis in 
structure-based studies. 
 
7.1.2  Structure-based study of ZINC database compounds on JIP binding 
site 
 
 The X-ray crystal structure of JNK1 with the truncated form of JIP1 was 
used to dock the 45673 compounds from the earlier ligand-based study on the 
JIP1 binding pocket of JNK1. A pharmacophore model was developed where the 
hydrogen bond interactions between Thr 159 in JIP1 with the residue Arg 127 in 
JNK1 was used to rapidly dock 45673 compounds and identify suitable poses as a 
starting point for molecular dynamics simulations. The ligand root-mean square 
deviation is used to measure the stability of the molecular dynamics trajectory and 
clustering of the trajectory was carried out to select a representative pose for 
analysis of binding interactions. A refined list of 1 compound was prioritized for 
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in vitro testing after showing a stable trajectory with potential hydrogen bonds 
that were formed with Arg 127. 
 
7.1.3 Structure-based study of ZINC database compounds on DFG binding 
site 
 
In the docking of DFG site compounds, as there were an insufficient 
number of compounds to perform a ligand-based study, a subset of purchasable 
compounds were chosen based on a diversity cutoff of 0.7 based on ChemAxon 
fingerprints. This became the starting number of compounds to use for the 
structure-based study. The compound list was refined and promising compounds 
were purchased and tested for in vitro activity. 
 
 The selected list of compounds that were tested for inhibitory activity on 
JNK2 did not show any significant binding at concentrations of up to 40µM. 1 
compound showed 19 % inhibition at 40 µM on JNK2, and 1 compound showed 
20 % inhibition at 40 µM on JNK1. 
 
7.1.4 in silico model of human and zebrafish PXR activators 
 
 Using the X-ray crystal structure of human PXR and a homology model of 
zebrafish PXR, an in silico model was developed to correlate the amount of 
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CYP3A4 gene expression with binding orientation of various approved drugs to 
human and zebrafish PXR. 
 
 Through a workflow process of combining docking with molecular 
dynamics, the binding orientation for 15 compounds were identified where 
structural interactions in each compound and 3 conserved residues in human and 
zebrafish PXR were identified to be important for PXR activation. These results 
could potentially be used to model other drug or chemical compounds in human 
and other species’ PXR to predict the extent of metabolism of the compound and 
CYP3A4 expression and activity and reduce the costs in carrying out in vitro and 




 Among the limitations of the ligand-based study, the relative lack of 
positive compounds in the training set and validation set and the unknown 
inhibitory activity profile in the putative negatives dataset affect the accuracy of 
the model and hence, the actual number of true positives and false positives 
identified from screening the ZINC chemical library are not known.  
 
 Structure-based studies were carried out to identify JNK inhibitors and 
PXR activators. Although molecular dynamics are able to form more accurate 
prediction models than docking with and without pharmacophore constraints, it is 
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highly dependent on available 3-dimensional structural information and site-
directed mutagenesis studies that are available in the literature. 
 
7.3 Future work 
 
 The next phase of this research would be to carry out in vitro tests on 
prioritized compounds, and additional molecular dynamics studies on compounds 
which met the docking with pharmacophore constraints filter, but were not 
selected for molecular dynamics studies and in vitro testing due to time and 
budget constraints. As only 1 compound out of the 17833934 compounds in the 
ZINC database were chosen for in vitro tests, with an ever increasing number of 
diverse chemicals being added to the database every month, there remains a very 
large chemical space to sample and a very large knowledge gap with regard to 
identifying potential JNK1 and JNK2 inhibitors, targeting two different active 
sites. 
 
 One possible approach to consider in future work would be to use ligand-
based 3D pharmacophore models as an additional prefiltering tool to refine the 
model and to sample the large and diverse chemical space more accurately as this 
method has been reported in the literature to be useful as a complementary 





 In addition, as the initial goals of the in vitro tests were to carry out tests 
for biological activity, there remains this knowledge gap where the identified 
positive compounds are not known which active site it binds to and in which 
conformation. Hence, further work might possibly include finding additional 
collaborators to carry out X-ray crystallography studies or nuclear magnetic 
resonance imaging studies to determine the location of the active site and the pose 
that the compound adopts to bind to the protein and induce the biological activity 
for identified JNK inhibitors or PXR activators. 
   
 Another possible further work will also include carrying out similar virtual 
screening studies on different JNK isoforms JNK2 and JNK3 to further screen and 
identify novel selective inhibitors that target only one JNK isoform. This is 
because JNK1, JNK2 and JNK3 are located in varying amounts in different parts 
of the human body as revealed by Northern blot analysis on different mammalian 
cell lines, and current research show that inhibition or gene-knockout of only one 
JNK isoform has a therapeutic effect in reducing the severity of a disease in in 
vitro and in vivo experiments, but gene-knockout of two or more could be lethal 
instead[36,191,192]. Hence, this aspect of research will address the safety aspect 
of developing a selective inhibitor of only one or two JNK isoforms, and hence 





 Another additional further work would include working further with 
collaborators to obtain biological activity on PXR to refine and improve on the 
model to be able to predict additional FDA approved drugs or xenobiotics more 
accurately by attempting to determine the amount of agonist or antagonist 
activity, together with the degree of binding and possible binding poses through 
additional docking and molecular dynamics studies. 
 
7.4 Dual-targeting approach and polypharmacology 
 
 The dual-targeting approach based on the concept of polypharmacology is 
gaining more interest in recent years. There are two possible interpretations to this 
approach. The first interpretation refers to the design of compounds that target 
two or more proteins involved in a disease process simultaneously. An example 
would be to design inhibitors that could inhibit both the JNK and p38 enzymes for 
possible treatment of cancer where it involves multiple different enzymes and 
pathways. To consider such an approach for a computational study, a disease must 
be chosen first, and then the docking of compounds must be carried out to several 
proteins involved in the disease. However, docking to several proteins is not a 
trivial task as each protein is unique and requires separate refinement to the 
docking procedure. Thus, based on the time available, the design of inhibitors for 




The second interpretation refers to the design of compounds that can bind 
to two binding sites in the same protein simultaneously.  Among the 191 
compounds that target the JIP binding site of JNK, the set of compounds 
published by Chen et al[37] were discovered to bind to both the ATP binding site, 
as well as the JIP binding site. Technically, it is possible to design such dual 
targeting drugs in this study. However, unlike the current design approach being 
used in this study, which involves screening of commercially available 
compounds, which could be easily bought and tested using kinase assay kits, 
testing such dual targeting drugs will not be as straightforward due to the need to 
find additional collaborators that are able to synthesize and test the compounds. 
For this reason, this approach is not given priority at this stage in the research 
project. However, this approach might be included in further studies when the 
opportunity arises. 
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